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Abstract 
The most common primary malignant brain tumor, glioblastoma, is uniformly 
fatal.  Current therapy provides only incremental benefits in survival and is often 
incapacitating owing to limits defined by nonspecific toxicity.  By contrast, 
immunotherapy offers a particularly promising approach, and has the theoretical 
potential to target and eliminate malignant cells with unprecedented specificity.  The 
goal of this dissertation is to apply recombinant technologies to develop a new immune-
based therapy for patients with malignant glioma.  This work will span the design, 
production, and preclinical testing of a novel bispecific antibody designed to redirect T 
cells against a tumor-specific mutant of the epidermal growth factor receptor, EGFRvIII. 
Chapters 1 and 2 will provide an overview of broad topics in antitumor 
immunotherapy and immune biology, with special focus on concepts as they relate to 
tumors of the central nervous system.  In addition, the history and current state of 
bispecific antibodies, particularly those of the bispecific T-cell engager (BiTE) subclass, 
as well as their potential role in the treatment of malignant disease, will be considered in 
detail.  Data presented in Chapter 3 will describe our approach to generating novel 
bispecific tandem single-chain antibody reagents, while experiments in Chapter 4 will 
demonstrate the capacity of one of these molecules, an EGFRvIII-specific BiTE, to 
achieve antitumor efficacy both in vitro and in vivo using murine models of glioma.  
Addressing a major barrier to the translation of immune therapies for cancer, chapter 5 
 v 
will establish a potential role for BiTEs in overcoming cell-mediated immune 
suppression associated with malignant disease.  Lastly, Chapter 6 and 7 will report on 
emerging areas of study, including the use of syngeneic, transgenic murine systems, and 
strategies by which BiTEs may be propelled rapidly into early phase clinical trials.   
In summary, separating BiTEs from other available immunotherapeutic 
approaches, our work in this field suggests that BiTEs are (1) highly-specific molecules 
that greatly reduce the risk of toxicity, (2) have the ability to penetrate the blood-brain 
barrier and accumulate in intracerebral tumors, and (3) may potentially overcome 
multiple mechanisms of immunosuppression present in patients with glioblastoma.  
Together, these studies have the potential to improve the clinical management of 
patients with glioblastoma through the generation of a novel therapeutic.
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1 Overview of Brain Tumor Immunotherapy and 
Immunobiology   
1.1 Permissions and Collaborative Work 
This dissertation contains original material as well as excerpts of text and figures 
from published articles, which were reproduced with permission in accordance with 
journal and publisher policies as described in Appendix.  Although this dissertation is 
representative of primary work performed by the candidate, assistance was graciously 
received on several occasions from collaborators listed in Acknowledgements.  
1.2 Introduction to Overview 
Of all causes of death, cancer is perhaps the most devastating; it currently 
represents approximately one of every four deaths in the United States and boasts an 
economic impact outweighing that of any other disease worldwide (Jemal et al., 2010).  
Relatively little progress has been made in terms of improving prognosis for advanced 
stage cancers over the past 40 years (Bailar and Gornik, 1997).   
Glioblastoma (GBM) is the most common and most aggressive primary 
malignant brain tumor.  Despite numerous advances in therapy—including image-
guided surgical resection (Kelly, 1992), high-dose external beam radiotherapy, 
antiangiogenic treatments (Vredenburgh et al., 2007), and chemotherapy—patients with 
GBM live less than an average of 15 months from the time of diagnosis (Stupp et al., 
2009).  Moreover, these treatments are often non-specific and result in incapacitating 
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damage to surrounding normal brain and systemic tissues.  A promising alternative is 
the use of the immune system, which has the theoretical capacity to eliminate neoplastic 
cells while leaving healthy cells intact.  Although first proposed over a century ago, the 
concept of antitumor immunotherapy has historically struggled to successfully translate 
effective treatments for patients with cancer.  This changed dramatically in 2010 after 
pivotal approvals by the Food and Drug Administration for immune-based cancer 
treatments, sipuleucel-T (Kantoff et al., 2010) and ipilimumab (Hodi et al., 2010), in the 
treatment of hormone-refractory prostate cancer and metastatic melanoma, respectively.  
Despite these recent advances, the use of immunotherapy as a standard-of-care 
treatment for GBM has yet to be realized.  A number of promising approaches are 
currently in development towards this end, and a broad understanding of their 
applications particularly in the context of intracerebral tumors represents an emerging 
priority. 
Table 1:  Historical perspective on progress in therapy for brain tumors. 
Year Milestone Median Survival 
1887 First successful surgical removal of a brain tumor 6 months 
1970s First promising chemotherapy for glioma (BCNU)  
1975-80 Radiation established as standard treatment for GBM 9 months 
1980s Gamma knife (stereotactic radiosurgery) is introduced  
2003 Chemotherapy carmustine (BCNU) “wafer”  
2005 Oral chemotherapy temozolomide receives approval 14.6 months 
2008 Bevacizumab (Avastin) approved for recurrent GBM  
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1.3 Central Nervous System Immune Privilege 
Despite conventional notions of CNS immune privilege, growing evidence 
supports that both immune cells and antibodies have the capacity to penetrate and treat 
tumors in the brain.  The following section will provide a historical perspective on this 
subject, as well as summarize more recent findings as they pertain to CNS immune 
access, particularly in the context of malignancy and antitumor immunotherapy. 
1.3.1 Classical Experiments and Emerging Ideology 
Antitumor immunotherapies, in the context of intracerebral tumors, encounter a 
distinct set of challenges, one of the most prominent being that of central nervous 
system (CNS) immune privilege.  The first studies to suggest the concept of limited 
immune surveillance in the CNS and other select tissues were first reported in 1948 by 
Sir Peter Medawar, who showed that allogeneic tissue grafts transplanted into the brains 
of experimental animals were not rejected (Medawar, 1948).  Later research in the area of 
neuro-immunology would support this finding based on unique characteristics that are 
now generally associated with the CNS:  the presence of a specialized blood-brain 
barrier (BBB) and the absence of conventional draining lymph nodes as well as resident 
antigen-presenting cells (APCs) within the brain (Hart and Fabre, 1981, Fabry et al., 
1994). 
While the CNS certainly exhibits immune privilege to some degree, a growing 
body of data suggests that its isolation from the immune system is not as complete as 
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once believed.  For instance, despite the BBB, immune cells have been shown to traffic to 
the brain relatively frequently (Owens et al., 1994, Engelhardt and Ransohoff, 2005, 
Hickey, 1991), and, contrary to what was previously thought, antigen egress via 
cerebrospinal fluid (CSF) compartments and cervical lymphatics also appears to occur 
(Cserr and Knopf, 1992, Goldmann et al., 2006).  Furthermore, it has been proposed that 
specialized microglia (Gehrmann et al., 1995) along with astrocytes (Aloisi et al., 2000) 
and certain cells of the choroid plexus epithelium (Serot et al., 1997) are able to mediate 
human leukocyte antigen (HLA) presentation, thereby functioning as surrogate APCs 
within the CNS.  
1.3.2 Crossing the Blood-Brain Barrier 
As previously mentioned, immune cells, specifically activated T lymphocytes, 
have the ability to penetrate the BBB under normal physiological conditions.  This was 
first appreciated when experimental animals were injected intravenously with 
radioactively labeled T cell blasts, which were subsequently tracked to the CNS 
(Engelhardt and Ransohoff, 2005).  Naïve T lymphocytes, however, are significantly 
restricted from entering the CNS, suggesting that penetration past the BBB is possible 
only after activation takes place (Mitchell et al., 2008a).  When it does occur, lymphocyte 
extravasation into the brain parenchyma is a highly-regulated process mediated by 
several well-characterized adhesion molecules and chemotactic factors (Engelhardt and 
Ransohoff, 2005).  Once inside the CNS compartment, whether T lymphocytes 
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proliferate and differentiate within the brain microenvironment has yet to be 
established, as previous studies differ on this point; nevertheless, it has been shown that 
these cells do remain in the CNS for longer periods of time if given the opportunity to 
interact with their cognate antigen  (Deshpande et al., 2000, Masson et al., 2007).   
Central-memory T lymphocytes that alternatively enter the CNS via the choroid 
plexus (Ransohoff et al., 2003) flux continuously throughout subarachnoid spaces, and 
have purportedly significant roles in routine CNS immunosurveillance.  Subarachnoid-
space macrophages and pericytes associated with CNS microvasculature are both 
considered to be critical in the presentation of recall antigens to this T cell population.  
At any given time, T lymphocytes represent over 80% of the approximately 150,000 cells 
normally found in the CSF of healthy individuals (Engelhardt and Ransohoff, 2005).  As 
an absolute number, this somewhat diminutive quantity of cells may not be particularly 
relevant to immune responses within the brain parenchyma; however, it seems that 
these cells are relatively CSF-enriched, given that lymphocytes typically compose less 
than 5% of all leukocytes present in circulating blood.    
In its intact state, the BBB is thought to be poorly permeable to antibodies.  This 
assumption stems from the observation that CSF titers in normal individuals are 
relatively low, especially in comparison to those measured in peripheral blood.  
Generally, the rate of immunoglobulin diffusion into the CNS varies depending on the 
molecular weight of a given protein (Pardridge, 1991); as an example, the physiological 
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CSF/serum ratios for IgM and IgG have been quoted to range from 0.005% to 0.025% and 
0.16% to 0.32%, respectively, reflecting the difference in size between these molecules 
(Bickel, 1995).  Although these limited ratios undoubtedly evidence CNS immune 
privilege to some degree, classic animal experiments have verified that, after both active 
and passive immunizations, corresponding antibodies can be detected within the CNS, 
specifically the brain, spinal cord, and CSF (Freund, 1930).  However, the reported 
fraction eventually isolated from these areas was again notably small—0.1 to 1% of that 
found in serum.       
The theoretical possibility that even small amounts of antibody can cross the BBB 
and have physiologically relevant effector functions in the CNS is supported by the 
recent development of promising vaccines for patients with Alzheimer’s disease (AD).  
These vaccines target amyloid-β (AB), the cleavage product of amyloid precursor 
protein (APP), mutations in which have been shown to lead to parenchymal amyloid 
plaque accumulation (Hardy, 1997, Selkoe, 1999) in addition to other pathological 
features and clinical manifestations of AD (Lue et al., 1999, Lahiri et al., 2005).  Initial 
experiments using transgenic mice expressing mutant APP have shown that active 
immunization with the AB peptide reduces plaque burden and improves behavioral 
endpoints (Koller et al., 2004, Brendza and Holtzman, 2006, Schenk et al., 1999).  This 
provided the first evidence that an immune response can be used as a potential 
treatment for AD, in theory by preventing formation of amyloid deposits and mediating 
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clearance of preexisting plaques.  Subsequent studies confirmed that the therapeutic 
effects of the vaccine are, at least in part, due to an antibody-mediated mechanism.  This 
was primarily demonstrated by animal experiments showing that peripherally 
administered AB-specific antibody enters the CNS, localizes to plaques, and achieves 
amyloid clearance mimicking that observed in previous mouse studies employing active 
immunization strategies (Bard et al., 2000, Bacskai et al., 2001).  Several hypotheses have 
been offered regarding the mechanism behind antibody-mediated plaque clearance in 
AD (St George-Hyslop and Westaway, 1999, Duff, 1999).   Of these, one prominent 
theory states that passively administered antibody sequesters AB-peptide in the 
periphery without crossing the BBB, thereby generating a concentration gradient 
favoring efflux out of the brain (DeMattos et al., 2001).  Other suggested antibody 
mechanisms rely on passage of antibody across the BBB; these include direct plaque 
disaggregation (Solomon et al., 1997) and Fc receptor-mediated microglial phagocytosis 
(Bard et al., 2000).  
Given these conclusions, the concept of BBB permeability in the absence of frank 
inflammation appears to be garnering support.  However, it has long been asserted and 
widely-accepted that in the presence of neuroinflammatory disease states—including 
experimental autoimmune encephalitis (EAE), meningitis, and cancer—the BBB 
undergoes changes that alter its ability to block the migration of leukocytes and serum 
proteins into the CNS (de Vries et al., 1997).  Furthermore, by virtue of their existence, 
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paraneoplastic syndromes clearly demonstrate that such changes in the BBB occur, and 
that these changes are in fact clinically significant.  Most paraneoplastic neurological 
disorders (PND) are likely immune mediated (Dalmau and Rosenfeld, 2008), as 
suggested by the demonstration of antineural antibodies in the CNS of patients with 
peripheral tumors.  These antibodies represent the body’s natural immune reactivity 
against systemic tumor antigens, and cross-reactivity with neurological structures has 
been found to result in significant morbidity.  A number of paraneoplastic antibodies 
have been cited in the involvement of PND pathogenesis; these include anti-Hu, anti-Yo, 
anti-Ri, anti-CV2/CRMP5, anti-Ma, and anti-amphiphysin antibodies (Dalmau and 
Rosenfeld, 2008).   
Since pathological antibodies have been shown to cross the BBB in the context of 
malignancy, it follows that peripherally administered therapeutic antibodies should also 
have access to the intracerebral environment with physiologically relevant outcomes.  
The development of radio-labeled monoclonal antibodies for the diagnosis and 
treatment of brain tumors was first explored by Day and coworkers in 1965 (Day et al., 
1965), and since then, numerous studies have supported that monoclonal antibodies 
(mAbs) are capable of localizing to intracerebral malignancies.  Using radioiodinated 
anti-tenascin mAb 81C6, our group has shown that not only does 81C6 exhibit 
therapeutic activity in mice with intracranial human glioma xenografts, but that 
selective tumor localization also occurs in patients with a variety of intracranial 
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malignancies following peripheral administration of the antibody (Zalutsky et al., 1989).  
However, tumor-specific uptake of 81C6 remained quite low at less than 5 x 10-3 % of the 
injected dose per gram, and nonspecific antibody accumulation also took place in other 
tissues besides the brain including the liver, spleen and bone marrow.  In contrast to 
what was observed with 81C6, results from later human studies using radiolabeled 
chimeric ch806, a mAb specific for the mutated epidermal growth factor receptor, 
EGFRvIII, suggest that higher-percentage BBB penetration may be achieved in the 
absence of cross-reactivity with systemic antigens, effectively creating an intracerebral 
antigen sink at the tumor site (Scott et al., 2007a).  Using single-photon emission 
computed tomography (SPECT), this potential effect was observed given the 
physiological localization of Indium-111-labeled ch806, which was noted to accumulate 
within intracranial target lesions without visual evidence of nonspecific, residual 
binding in normal tissues. 
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Figure 1:  Targeting of glioma by radiolabeled chimeric monoclonal antibody directed 
against the EGFRvIIII tumor antigen.   
(A–C) Planar images of the head and neck obtained on day 0 (A), day 3 (B), and day 7 (C) 
after infusion of 111In-ch806. Initial blood pool activity is seen on day 0, and uptake of 
111In-ch806 in an anaplastic astrocytoma in the right frontal lobe is evident by day 3 
(arrow) and increases by day 7. (D–F) Tumor-specific uptake of 111In-ch806 (arrow) is 
demonstrated in a SPECT image of the brain (D), 18F-FDG (FDG, Fluorodeoxyglucose) 
positron emission tomography (E), and MRI (F).  Figure reproduced according to journal 
guidelines (Scott et al., 2007a). 
 
1.4 Tumor-Associated Rejection Antigens 
The landmark paper published over two decades ago by van Pel and Boon 
rekindled the then waning interest in cancer vaccine development when it suggested 
that even non-immunogenic tumors display sufficiently “foreign,” and therefore 
immunologically susceptible, antigen profiles (Van Pel and Boon, 1982).  Since that time, 
a great deal of effort has gone towards characterizing a variety of human tumor 
antigens, the majority of which can now be placed into one of two main categories:  
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those consisting of over-expressed normal gene products or, alternatively, those derived 
from mutations in somatic genes (Gilboa, 2004, Gilboa, 1999).   
Most well-characterized targeted tumor antigens isolated to date correspond to 
over-expressed proteins that are also present in normal cells, two examples of which 
include CD20 and erbB2, proteins associated with lymphoma and breast cancer, 
respectively.  The ability of antigens in this category to mediate optimal tumor rejection, 
however, is often compromised by the fact that proteins that are also found on normal 
cells have the potential to trigger immunologic tolerance to varying degrees.  Notable 
exceptions to this limitation include antigens associated with fetal gene products, such 
as carcinoembryonic antigen (Kass et al., 1999), or those expressed solely in 
immunoprivileged, tissue-specific sites like the testis.  The latter group includes the 
melanoma MAGE, GAGE (Van den Eynde et al., 1995), and BAGE (Boel et al., 1995) 
family antigens, all of which, due to their limited expression, trigger little to no tolerance 
and should therefore make ideal tumor rejection antigens.   
Cancer vaccination protocols that effectively target normal gene products 
invariably pose the risk of autoimmune toxicity (Gilboa, 2004).  This untoward effect can 
be avoided to some extent by directing the immune response against a mutated protein 
specific only to tumor cells.  As targets, these antigens have the advantage of avoiding 
central tolerance mechanisms, in theory making them more suitable for tumor rejection.  
However, a limitation of these antigens is that they are generally patient-specific as they 
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often reflect random mutations associated with the inherent genetic instability of tumors 
(Lengauer et al., 1998, Loeb, 2001).  Thus, to the extent that mutated gene products are 
incidental to the oncogenic process, they are conceivably restricted in their use as 
practical targets of widely applicable cancer vaccines.  Conversely, although the majority 
of somatic mutations in tumors does appear to be sporadic (Lennerz et al., 2005), recent 
studies using high-throughput screening have suggested that several functional 
mutations associated with, rather than incidental to, the oncogenic process are in fact not 
random, and that these variants are consistently shared among patients (Thomas et al., 
2007).  The challenge then, is to isolate and target these ideal antigens:  frequent, highly 
specific, oncogenic mutations that are also absent from normal tissues, thereby avoiding 
the risk of autoimmunity.  To date, few such antigens are known, though their discovery 
represents a potential boon for the further development of effective antitumor 
immunotherapies.    
1.5 Glioma-Induced Immune Suppression 
Gliomas are also known to potentiate a hostile environment that can antagonize 
the development of efficacious antitumor immune responses.  Immune suppression in 
patients with GBM is manifested by several metrics including low peripheral 
lymphocyte counts, depressed skin reactivity to recall antigens, and impaired T-cell 
function with a counterproductive Th2 cytokine skew.  A number of pathways have 
been shown to contribute to the development of this pro-tumorigenic milieu.  Like other 
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cancers, gliomas secrete immunosuppressive cytokines including prostaglandin E2 
(PGE-2), transforming growth factor (TGF)-ß and interleukin (IL)-10, leading to 
potentiation of immune resistance through down-regulation of major histocompatibility 
complex (MHC) expression and suppression of  both normal T-cell proliferation and 
dendritic cell (DC) maturation (Heimberger and Sampson, 2011).  In addition to soluble 
secreted factors, specific subsets of immune regulatory cells have also been cited as 
central mediators of tumor-associated immune suppression.  Among these include 
tumor-associated myeloid-derived cells and macrophages (Pollard, 2004), as well as a 
subset of T cells known as regulatory T cells (Tregs), which have perhaps been most 
frequently implicated.  Tregs have not only been shown to be present at increased 
proportions in both the peripheral blood and tumors of patients with GBM (Fecci et al., 
2006, El Andaloussi and Lesniak, 2006), but their presence has also been correlated with 
the overall malignant behavior of these tumors (Heimberger et al., 2009).  Tregs are known 
to suppress effector T-cell responses, specifically by restricting IL-2 production and 
inducing T-cell anergy.  Importantly, Treg depletion has been positively associated with 
enhanced immunity in patients with GBM (Sampson et al., 2012), and in vivo impairment 
in tumor-bearing mice has been shown to prolong survival (El Andaloussi et al., 2006).   
Gliomas not only possess low levels of surface MHC, but are also known to 
express costimulatory inhibitory molecules which may lead to direct inhibition of 
immune responses (Parsa et al., 2007).  These interactions may be manipulated by GBM 
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cells to unfavorably alter signaling through immune checkpoints such as programmed 
cell death (PD)-1 and cytotoxic T-lymphocyte antigen (CTLA)-4.  Other areas of 
investigation have underscored the role of signal transducer and activator of 
transcription (STAT)3 in regulating inflammatory responses.  Interestingly, the STAT3 
pathway in both immune cells (Kortylewski et al., 2005) and tumor cells (Wei et al., 2010) 
has been shown to potentiate immune suppression, leading to generalized impairment 
of effector responses.  As such, therapies designed to modulate STAT3 as well as 
costimulatory signaling (Fecci et al., 2007) to enhance antitumor immune responses are 
among many promising therapies for GBM under current investigation.  
1.6 Clinical Applications of Glioma Vaccines and Immune-Based 
Approaches 
The overall goal of tumor immunotherapy is to develop or enhance immune 
responses against established disease, even in cases where natural immune surveillance 
has either failed or been rendered less effective by mechanisms of tumor-associated 
immune evasion.  To date, a wide range of immune-based strategies have been 
developed towards this end.  Among these include passive infusion with antibodies as 
well as adoptive transfer of tumor-reactive lymphocytes, cytokine-based stimulatory 
treatments, and an array of active immunization methods in the form of vaccines 
administered to elicit host immunity against tumor cells.  The following sections will 
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introduce the basic principles for several of these modalities, with a focus on major 
advances that have emerged from representative clinical trials. 
1.6.1 Active Immunotherapy for Brain Tumors 
Active immunotherapies seek to achieve priming of host immunity and 
immunological memory against tumors through the use of vaccines.  Over the years, 
approaches to establishing active immunotherapy against brain tumors have varied 
widely, and in some cases have led to successful advancement toward phase III 
randomized studies.   
1.6.1.1 Autologous Tumor Cell Vaccines 
One of the oldest methods of active immunization for cancer consists of direct 
vaccination with tumor cells, which in some cases have been modified to increase 
immunogenicity.  In this approach, autologous tumor cells are resected during surgery 
and, following inactivation by radiation, are incorporated into a vaccine to elicit immune 
reactivity in the individual from whom the tumor was isolated.  Early clinical studies 
have been performed with tumor cells that have been genetically modified to enhance 
biological activity, either through inhibition of immunosuppressive factors (e.g., TGF-ß) 
(Fakhrai et al., 2006), or increased secretion of immune potentiating cytokines including 
IL-4 (Okada et al., 2000), IL-12 (Ehtesham et al., 2002) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF).  Overall, approaches using autologous tumor cell 
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vaccines have been shown to elicit antitumor immune responses and to be well-tolerated 
without severe adverse events.  
Compared to other methods, vaccination with whole tumor material has a 
distinct advantage of eliciting immune responses that are tailored to each individual 
tumor, thereby accounting for the broad interpatient variability and heterogeneous 
antigen expression associated with gliomas.  However, for the same reasons, whole 
tumor vaccines are conversely hampered by a certain lack of methodological 
standardization across trials and also in a technical sense owing to the need for a 
significant amount of tumor tissue.  Other disadvantages of using whole tumor cells 
include the theoretical dilution of tumor antigens by normal cellular components, and 
difficulties associated with isolating and characterizing antigen-specific immune 
responses following vaccination. 
1.6.1.2 Peptide Vaccines 
Peptide vaccines comprise delivery of a tumor antigen, often in conjunction with 
an immune-stimulating adjuvant.  Peptide vaccines represent an especially attractive 
platform for active immunotherapy, given that they are relatively easy to manufacture, 
can be tailored to individual or mixed antigens, and can be standardized in formulations 
across multiple institutions.  Several groups have demonstrated that peptide vaccines 
can be administered in the setting of malignant glioma to achieve tumor-specific 
immune responses in clinical trials.  One notable peptide vaccine, the EGFRvIII-specific 
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PEP-3-KLH (CDX-110) formulation, has been shown to elicit EGFRvIII-specific immune 
responses, leading to subsequent elimination of EGFRvIII-expressing tumor cells in mice 
and humans (Sampson et al., Sampson et al., 2009, Heimberger et al., 2003).  Although 
Phase 2 clinical studies of peptide vaccines against EGFRvIII and Wilms tumor 1 (WT1) 
(Izumoto et al., 2008) have yielded encouraging results, one concern is that targeting 
single antigens may inadequately address the diverse and heterogeneous nature of 
malignant gliomas, leading to eventual outgrowth of antigen-negative recurrence and 
immune escape.  As such, personalized vaccines in the form of several peptide 
combinations have also been attempted, which have also demonstrated the capacity to 
develop specific immunity and favorable responses in clinical trials (Yajima et al., 2005).  
1.6.1.3 Dendritic Cell Vaccines 
Dendritic cells (DC) are “professional” antigen-presenting cells whose main 
function is to modulate immune responses through the processing and presenting of 
antigenic material to effector T cells.  Given recent advances in their ex vivo generation 
and manipulation, DCs have emerged as a vaccine platform with great potential for 
patients with GBM.  To manufacture a DC vaccine, autologous DCs are harvested from 
peripheral blood or bone marrow and exposed in vitro to tumor antigens in the form of 
tumor homogenate, peptides, or even genetic material encoding antigens of interest, 
prior to injection back into the patient.  Several clinical trials have demonstrated that 
DCs loaded with tumor homogenate or lysate are well-tolerated (Wheeler et al., 2008, De 
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Vleeschouwer et al., 2008), and may be complemented by certain adjuvant therapies 
(e.g., Toll-like receptor agonists) (Prins et al., 2011) to produce antitumor T-cell 
responsiveness.  In addition, recent efforts to integrate tumor-pulsed DC vaccines with 
measures of standard postoperative care have met with early success (Ardon et al., 
2010).   
Instead of whole tumor lysate, peptides have also been used as an alternative 
source of antigenic material for the DC vaccine platform.  One notable peptide-based DC 
vaccine targeting EGFRvIII has successfully demonstrated the capacity to elicit 
EGFRvIII-specific immune responses without serious adverse events (Sampson et al., 
2009).  Other studies of peptide-pulsed DC vaccines include DCs loaded with multi-
epitope antigen formulations either through the use of acid-eluted, tumor-associated 
MHC class I peptides (Yu et al., 2001, Liau et al., 2005) or synthetic peptide 
combinations—recent examples of the latter have targeted glioma-associated antigens 
including HER2, TRP-2, EphA2, IL-1Rα2, AIM-2 YKL-40 and gp100 (Okada et al., 2011, 
Phuphanich et al., 2013).  Lastly, efforts have also been developed to elicit antitumor 
immune responses using DCs loaded with autologous, tumor-antigen encoding RNA; 
early clinical trials using this strategy have demonstrated safety and feasibility, 
particularly in the setting of pediatric brain cancers (Caruso et al., 2004, Caruso et al., 
2005). 
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1.6.2 Adoptive Immunotherapy for Brain Tumors 
In general, adoptive immunotherapy refers to the ex vivo activation and 
expansion of immune cells which are then administered to treat patients through 
intratumoral or intravenous infusion.  To date, the most encouraging results for CNS 
tumors have been achieved in the setting of melanoma brain metastases, where adoptive 
transfer of either autologous tumor-infiltrating lymphocytes (TIL) or T-cells genetically 
modified to target tumor antigens resulted in complete response rates of 41% and 22%, 
respectively (Hong et al., 2010).  Despite this promise, adoptive transfer therapies for 
high-grade glioma have not yet realized this level of success.  Historically, clinical trials 
of adoptive immunotherapy for glioma have attempted transfer of various cell types 
including lymphokine-activated killer (LAK) (Jacobs et al., 1986) cells as well as 
cytotoxic T lymphocytes (CTLs) that have been isolated from expanded tumor-
infiltrating lymphocytes (TIL) (Quattrocchi et al., 1999) or lymph nodes from vaccinated 
patients (Plautz et al., 2000).  Although several groups have demonstrated the general 
feasibility of these approaches, therapeutic outcomes have been relatively modest, 
especially when taking into account the high levels of antitumor cytotoxicity observed 
during corresponding preclinical studies in vitro.  As such, current efforts seek to 
elucidate additional factors that may refine the translation of adoptive transfer therapies 
in vivo; among these include the identification of specific effector cell phenotypes 
predictive of antitumor responses, as well as improvements to enhance persistence of 
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infused cells, either through host-conditioning lymphodepletive regimens or the 
concomitant use of homeostatic cytokines (e.g., IL-7, IL-15).   
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Table 2:  Data from representative immunotherapy clinical trials for glioma. 
Agent delivered Phase Institution Median Survival 
PEP-3-KLH + GM-CSF 
(ACTIVATE) 
II Duke University Medical 
Center/The University of 
Texas MD Anderson 
Cancer Center/Celldex 
2.4 years; newly 
diagnosed; n = 23. 
PEP-3-KLH + GM-CSF 
with TMZ (ACT II) 
II Duke University Medical 
Center/The University of 
Texas MD Anderson 
Cancer Center/Pfizer 
1.9 years; newly 
diagnosed; n = 21. 
DCs + PEP-3-KLH I/II Duke University Medical 
Center 
1.8 years; newly 
diagnosed; n = 14. 
Personalized peptide 
vaccines (4) 
I Nigata University 1.7 years; recurrent 
GBM; n = 17. 
DCs + CMV II Duke University Medical 
Center 
not reached but will 
exceed 1.6 years; newly 
diagnosed GBM; n = 13. 
DCs + autologous tumor 
lysate 
II University of Leuven 
and Wurzburg 
 0.8 years from relapse; 
recurrent GBM; n = 56. 
DCs + acid=eluted 
tumor peptides 
I/II Cedars Sinai Medical 
Center 
1.3 years; newly 
diagnosed GBM; n = 7. 
DCs + tumor 
homogenate 
II Cedars Sinai Medical 
Center 
1.8 years; newly 
diagnosed GBM; n = 11. 
1.6 years; recurrent 
GBM; n = 21. 
DCs + acid-eluted tumor 
peptides 
I UCLA 2.0 years; newly 
diagnosed and recurrent 
GBM; n = 12. 
Autologous tumor cells 
with antisense TGF-β 
I Advanced 
Biotherapies/NovaRx 
1.4 years; n = 6. 
Poly-ICLC II North American Brain 
Tumor Coalition 
1.4 years; newly 
diagnosed GBM; n = 30. 
Autologous whole 
tumor with GM-CSF 
and adoptive transfer of 
CD3-activated cells 
II Tvax Biomedical 1.0 year; recurrent 
malignant glioma; n = 
19. 
Table adapted with permission (Heimberger and Sampson, 2011). 
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1.7 Experimental Allergic Encephalomyelitis  
It is likely that as immunotherapies become more potent, the risk of adverse 
immune side effects may increase.  This is especially true for immunotherapeutic 
platforms designed to target glioma-associated antigens that are shared with normal, 
healthy brain tissue; active immunization against these antigens could escalate the risk 
of uncontrolled CNS autoimmunity, similar to what has been observed in preclinical 
models of experimental allergic encephalomyelitis (EAE).  Importantly, following 
vaccination with tissue derived from human gliomas, lethal EAE or EAE-like toxicity 
has been documented in both non-human primates (Graf et al., 2002) as well as in 
human studies of immunotherapy for brain tumors (Bloom et al., 1973, Trouillas, 1973).  
These results are to some degree expected, given that gliomas are known to express both 
normal adult and fetal brain antigens, and because several preclinical protocols are 
already known to produce EAE upon immunization with CNS tissue. 
As such, the risk of autoimmune toxicity represents an ongoing concern for 
tumor vaccines that are not carefully selected for tumor-specificity.  However, as 
mentioned above, this issue can be avoided to some extent by redirecting immune 
responses against antigens that are expressed solely in gliomas and completely absent 
from all normal tissues.  To date, only few such antigens have been thoroughly 
characterized.  Among these include the tumor-specific mutant protein, EGFRvIII (Choi 
et al., 2009), as well as frequent and homogenous mutations associated with isocitrate 
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dehydrogenase 1 (IDH1) (Yan et al., 2009).  Also notable is the selective detection of viral 
antigens corresponding to human cytomegalovirus infection, which have been shown to 
be expressed in a high percentage of GBM tumors but not surrounding normal brain 
(Mitchell et al., 2008b, Cobbs et al., 2002).   
1.8 The EGFRvIII Tumor-Specific Antigen 
Among the many antigens that have been shown to be overexpressed on tumor 
cells, the type I epidermal growth factor receptor (EGFR) represents one of the most 
frequently implicated cell-surface markers for a wide range of human malignancies. 
Functionally, the EGFR has well-characterized roles in oncogenesis and tumor 
progression, and as such, amplification and overexpression of the EGFR gene is 
considered a poor prognostic indicator (Neal et al., 1990).  Regarding intracerebral 
cancers in particular, the EGFR gene is amplified in up to 50% and overexpressed in over 
90% of GBM specimens (Ekstrand et al., 1991, Jaros et al., 1992), suggesting significantly 
augmented cellular activity of this receptor in these tumors. 
The EGFR is a 170-kDa transmembrane glycoprotein, consisting of an 
extracellular ligand-binding domain and an intracellular region with tyrosine kinase 
functionality (Stoscheck and King, 1986).  Activation via stimulatory interactions with 
growth factors—including epidermal growth factor (EGF) and transforming growth 
factor-α—results in receptor dimerization and subsequent intracellular 
autophosphorylation on tyrosine residues, in turn leading to the activation of 
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downstream molecules associated with cellular mitogenesis and survival (Carpenter and 
Cohen, 1990).  Given the nature of these potentially oncogenic pathways, it was 
originally believed that the impact of EGFR on neoplastic processes was exclusively due 
to amplification of its corresponding gene.  However, it is now clear that many tumors, 
including GBM, also express rearranged, aberrant forms of the EGFR gene that have 
significant physiological relevance (Ekstrand et al., 1991, Frederick et al., 2000).  Several 
of these mutations have been reported in the literature and are typically associated with 
tumors that also exhibit extensive wild-type gene amplification (Libermann et al., 1985, 
Wong et al., 1992). 
The most common and well-characterized EGFR mutant was first identified in 
primary human GBM tumors and is commonly referred to as the EGFR class III variant 
(EGFRvIII).  EGFRvIII is a constitutively active, ligand-independent form of the EGF 
wild-type receptor (Hou et al., 1997, Batra et al., 1995), the expression of which has been 
shown to have tumorigenic effects, both augmenting proliferation and inhibiting 
apoptosis (Nishikawa et al., 1994, Batra et al., 1995).  Specifically, EGFRvIII has also been 
shown to promote greater cellular motility (Pedersen et al., 2004, Boockvar et al., 2003) 
as well as resistance to radiation and chemotherapy (Lammering et al., 2004b, 
Lammering et al., 2004a, Montgomery et al., 2000), characteristics often associated with 
highly malignant tumors.  
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A number of molecular mechanisms have been implicated in the oncogenic 
pathways coupled with EGFRvIII downstream signaling.  In the absence of ligand-
binding and dimerization, for example, EGFRvIII has been observed to constitutively 
interact with adaptor proteins central to the Ras cascade (Prigent et al., 1996, Chu et al., 
1997).  Similarly, growth advantage in cells expressing EGFRvIII has been attributed at 
least in part to elevated phosphatidylinositol (PI) 3-kinase levels and consequent 
activation of the c-Jun N-terminal kinase (JNK) pathway (Antonyak et al., 1998, 
Moscatello et al., 1998).  The respective involvement of, and interplay among, these 
signals in neoplastic processes have yet to be fully-described; however, it has been 
shown that malignant cells become dependent on these pathways to some extent, and 
that removal of such stimulation results in reduced cell survival (Weinstein, 2002). 
Structurally, EGFRvIII is an 801 base pair in-frame deletion of the wild-type 
receptor that corresponds to mRNA exons 2-7, the absence of which leads to the 
translation of a truncated extracellular domain.  A consequence of this deletion-mutation 
is the fusion of two otherwise distant portions of the molecule, which in turn creates an 
antigenic junction characterized by a novel glycine residue, flanked by amino acid 
sequences that are not typically adjacent in the wild-type receptor (Bigner et al., 1990, 
Libermann et al., 1985).  This tumor-specific epitope has been shown to be present on the 
surface tumor cells, yet completely absent from any normal adult tissues (Humphrey et 
al., 1990).   
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Figure 2:  Schematic diagram of the EGFR wild-type protein and EGFRvIII in-frame 
deletion. 
During the deletion amino acids 6 and 273 are split forming a novel glycine at the 
junction of amino acids 5 and 274.  PEPvIII is a 13 amino acid peptide with a terminal 
cysteine added to facilitate conjugation to KLH.  Figure reproduced with permission 
according to journal policies (Sampson et al., 2008)  
  
Immunohistochemical (IHC) analysis represents one of the most common assays 
used to identify the EGFRvIII mutant along with a number of second messenger 
molecules also expressed in malignant cells.  Alternative approaches to IHC which 
employ molecular techniques such as Western blotting and reverse transcription-
polymerase chain reaction assays (RT-PCR) are currently being explored and have 
confirmed the specific expression of EGFRvIII in human GBM specimens; to date, data 
derived from IHC studies have been shown to be consistent with results obtained using 
other methods (Feldkamp et al., 1999).  As evidenced by IHC, EGFRvIII is consistently 
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expressed in a wide variety of cancers, and can be found in approximately 20% of GBM 
specimens (Moscatello et al., 1995).  Within such tumor samples, the proportion of 
EGFRvIII-expressing cells has been shown to range from 37-86% (Wikstrand et al., 1997), 
suggesting that cells within EGFRvIII-positive tumors may translate the variant receptor 
with at least some level of homogeneity.  Thus, given its oncogenic properties, inherent 
tumor specificity, and frequent expression in malignancy, the EGFRvIII mutation 
represents a particularly attractive tumor-specific target for the development of anti-
cancer immunotherapies (Kuan et al., 2001, Wikstrand et al., 1998).   
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Figure 3:  Immunohistochemical analysis of EGFRvIII and other tumor associated 
messenger proteins in human astrocytoma.   
A, High-grade astrocytoma used in subsequent immunohistochemical assays 
(hematoxylin-eosin, original magnification ×400). B, Anti– epidermal growth factor 
receptor (anti-EGFR) wild-type immunohistochemistry showing strong diffuse 
cytoplasmic immunoreactivity, a pattern that is frequently associated with EGFR genetic 
amplification (original magnification ×400). C, Anti-EGFRvIII immunohistochemical 
reactivity exhibiting strong cytoplasmic localization. EGFRvIII immunoreactivity is most 
commonly encountered in tumors also exhibiting amplification of the EGFR locus 
(original magnification ×400). D, Anti-phosphatase and tensin homolog (anti-PTEN) 
immunoreactivity demonstrating 80% of tumor cells with cytoplasmic reactivity, a 
pattern associated with an intact PTEN status in the tumor (original magnification ×400). 
E, Anti–phospho-S6 immunohistochemistry revealing approximately 20% of tumor cells 
labeling, indicating this messenger is activated in this tumor (original magnification 
×400). F, Anti–phospho-Akt immunohistochemistry demonstrating approximately 80% 
of tumor cells labeling, indicating this messenger is activated in this tumor (original 
magnification ×400).  Figure reproduced with permission according to journal policy 
(McLendon et al., 2007) 
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1.8.1 Therapeutic Targeting of EGFRvIII 
Currently, a number of immunotherapeutic approaches targeting the unique 
EGFRvIII antigen are under investigation.  Although these were mentioned briefly in 
previous sections covering glioma vaccines and immune-based treatments, the 
remainder of this chapter will revisit therapeutic targeting of EGFRvIII in detail, with 
special attention to published studies regarding preclinical development as well as 
recent advances made toward translation in human trials.   
Given the technical difficulty and relatively high cost of dendritic cell (DC) 
vaccination therapy, the most promising and practical active vaccination format to date 
is a peptide derived from the novel fusion junction amino acid sequence.  PEPvIII (H-
Leu-Glu-Glu-Lys-Lys-Gln-Asn-Tyr-Val-Val-Thr-Asp-His-Cys-OH) (Moscatello et al., 
1997) is a well-characterized, EGFRvIII-specific, 14-mer peptide that has been shown, 
when coupled to keyhole limpet hemocyanin (KLH), to elicit both humoral and cellular 
immune responses.  Extensive experience has been reported with PEPvIII-KLH, which 
has clearly demonstrated the induction of considerable EGFRvIII-specific immune 
responses in both murine tumor models and early clinical trials.   
1.8.1.1 EGFRvIII:  Preclinical Studies 
Passive administration of EGFRvIII-specific antibodies Y10 and L8A4 (unarmed 
murine IgG2a and IgG1, respectively) has been shown to lead to significant tumor growth 
inhibition in subcutaneous (s.c.) murine melanoma models.  These studies, which use 
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syngeneic tumors transfected with a murine homologue of the variant receptor 
(msEGFRvIII), have shown that while these two monoclonal antibodies achieve 
therapeutic efficacy when given intraperitoneally, only those mice treated with Y10 
exhibit lasting tumor-free survival after treatment is discontinued (Sampson et al., 2000).  
Evidence from in vitro studies suggests that Y10 has the ability to mediate a wide range 
of effector functions when incubated with cells expressing msEGFRvIII.  These functions 
include the inhibition of DNA synthesis and cellular proliferation, as well as the 
activation of autologous, complement-mediated, and antibody-dependent cell-mediated 
cytotoxicity (ADCC).      
Active vaccination strategies targeted against msEGFRvIII in syngeneic murine 
tumor models have also proven to be effective.  Following intraperitoneal injection with 
DCs pulsed with PEPvIII-KLH, C3H mice that had previously been challenged with 
intracerebral tumors demonstrated a significant increase in median survival.  
Furthermore, all the mice in this study survived rechallenge with tumor, suggesting that 
immunization was sufficient to create long-term immunological memory against the 
msEGFRvIII antigen in this model system (Heimberger et al., 2002).  Following this 
experiment, similar studies were conducted in which C3H mice were treated using a 
one-time vaccination, this time with PEPvIII-KLH in complete Freund’s adjuvant as 
opposed to the DC vaccine.  This vaccine protocol also resulted in increased median 
survival and ultimately long-term survival in nearly half of the mice (Heimberger et al., 
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2003).  Notably, mice with tumors that failed to exhibit responses to the PEPvIII-KLH 
vaccine were found to have IHC evidence of downregulated or completely absent 
EGFRvIII expression, suggesting that antigen escape variants may be associated with 
failure to adequately treat some tumors. 
1.8.1.2 EGFRvIII:  Clinical Studies 
It has also been demonstrated in clinical trials that EGFRvIII-specific immunity 
can be induced with vaccines targeted against the EGFRvIII tumor specific antigen.  A 
number of EGFRvIII-derived cytotoxic T lymphocyte (CTL) epitopes have been 
characterized to date (Wu et al., 2006), and previous data has shown that EGFRvIII-
specific antibody titers, while absent in normal volunteers, may be detectable in patients 
with tumors expressing the mutant receptor (Purev et al., 2004).  It is still unclear 
however whether cellular or humoral responses will ultimately provide the critical 
mediators for specific antitumor eradication using our approach.  
The first clinical study evaluating the toxicity and potential efficacy of EGFRvIII-
based vaccinations began with a Phase I trial (VICTORI) (Sampson et al., 2009) 
conducted at Duke University Medical Center (PI:  John H. Sampson).  Fifteen adults 
with newly diagnosed GBM (WHO grade III or IV) were enrolled in the study; criteria 
for eligibility did not include EGFRvIII expression.  Of the fifteen patients, three did not 
ultimately receive vaccine due to progression of their tumors during external beam 
radiotherapy (ERBT).  Following gross total tumor resection and completion of EBRT, 12 
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patients underwent leukapheresis to obtain peripheral blood mononuclear cells 
(PBMCs) in preparation for DC generation and immunologic monitoring.  Prior to 
inoculation, DCs were pulsed for two hours with 500 μg PEPvIII peptide (Anaspec, San 
Jose CA) conjugated to KLH (Biosyn, Carlsbad CA).  In total, patients received up to 1.1 
x 108 DCs in three equal doses, injected intradermally every two weeks into the upper 
thigh, 10cm below the inguinal ligament.  Patients were followed for toxicity and 
evidence of radiographic or clinical progression.   
Patients in the VICTORI trial did not suffer serious adverse events exceeding 
Grade II toxicity at any DC dose tested (National Cancer Institute Common Toxicity 
Criteria).  Blood drawn from patients following vaccination showed ex vivo evidence of 
antigen-specific cellular and humoral immune responses.  Median survival for the 12 
patients was 18.7 months after vaccination (C.I.95 14.5, 25.6) and 22.8 months after 
histological diagnosis (C.I.95 17.5, 29).  These outcomes improve on what would have 
been expected by chance, according to Curran’s recursive partition analysis (Curran et 
al., 1993).   Eight of the 12 patients in this study belonged to group III, and the remaining 
4 belonged to group IV, which have estimated survivals of 17.9 and 11.1 months, 
respectively.  While 9 of the 12 patients in our study surpassed these estimates, the 
increase in survival was not statistically significant (P=0.083; binomial proportions), 
though these results may be negatively biased by the fact that EGFRvIII expression was 
not a criterion for inclusion in this Phase I toxicity trial.   
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Nevertheless, the outcomes associated with the DC-based, PEPvIII-specific 
vaccine were encouraging and warranted further testing at different centers; however 
the inherent cost and variability associated with autologous DC manufacturing made 
this approach impractical on a large scale.  Thus, given the success of preclinical studies, 
a Phase II multicenter trial (ACTIVATE) (Heimberger et al., 2006) was attempted 
without the use of DCs, instead administering PEPvIII-KLH directly in combination 
with granulocyte macrophage-colony stimulating factor (GM-CSF).   
ACTIVATE, a Phase II, multicenter clinical trial conducted at Duke (PI: John H. 
Sampson) and University of Texas, M.D. Anderson Cancer Center (PI: Amy B. 
Heimberger), enrolled 19 adults who all had EGFRvIII-expressing, newly-diagnosed 
primary GBM (WHO Grade IV).  Prior to receiving the KLH-conjugated peptide 
vaccines, patients underwent >95% volumetric tumor resection, along with standard of 
care radiation therapy with concurrent TMZ.  Vaccinations consisted of intradermal 
injections with 500μg PEPvIII-KLH (Anaspec, San Jose CA) and GM-CSF, administered 
near the inguinal region in the upper thigh, on alternating sides.  The first three vaccines 
were given biweekly, followed by monthly injections until radiographic evidence of 
tumor progression or death.   
Similar to what was observed in VICTORI, patients participating in ACTIVATE 
did not experience serious adverse events aside from local reactions at the injection site.  
This vaccine formulation was shown to elicit both humoral (Schmittling et al., 2008) and 
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delayed-type hypersensitivity immune responses specific for PEPvIII and EGFRvIII in a 
number of patients, and that detection of these responses predicts greater median 
overall survival (OS).  Median time-to-progression (TTP) following surgery in patients 
who received the vaccine is 12 months (n=12), exceeding a median TTP of 7.1 months 
(n=29) calculated from a historical matched unvaccinated control group (p=0.0058).  If 
and when tumors recurred, pathological samples were obtained and evaluated by IHC 
to determine EGFRvIII expression.  Of the specimens examined in this trial, none were 
found to contain cells that display positive staining for EGFRvIII,  
Following ACTIVATE, the ACT II trial was initiated (Sampson et al., 26: 2008 
(May 20 suppl; abstr 2011)), which enrolled a total of 21 patients who essentially 
followed the same treatment scheme as those in ACTIVATE, except for the addition of 
two different TMZ dosing schedules concurrent with vaccination cycles; patients either 
received 200mg/m2 TMZ x 5/28 days (ACT IIA [n=13]) or 100mg/m2 TMZ x 21/28 days 
(ACT IIB [n=8]).  While grade 2 TMZ-associated lymphopenia was observed in the 
majority of ACT II patients, it was found that all immune responses were unexpectedly 
either sustained or enhanced with successive TMZ treatments.  The seemingly 
paradoxical relationship between TMZ-induced lymphopenia and improved PEPvIII-
KLH-specific immunogenicity is currently under further investigation.  
In summary, these trials to date collectively show that vaccination with a peptide 
containing the PEPvIII tumor epitope safely elicits a specific immune response against 
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EGFRvIII, and that this approach might be effective against cancers bearing the variant 
antigen.  While the vaccine demonstrated significantly greater TTP and OS in GBM 
patients who have received the PEPvIII-KLH vaccine, definitive evidence for this 
promising effect will require confirmation from our ongoing randomized Phase III 
clinical trials.   
1.9 Discussion 
While the mechanisms underlying the beneficial effects of the EGFRvIII vaccine 
in patients with GBM are still unclear, it is our hope that additional experience with 
PEPvIII-KLH will elucidate our general understanding of various peptide vaccination 
strategies and their potential role in eliciting effective antitumor responses.  A number of 
issues regarding the specific targeting of EGFRvIII by this peptide vaccine have yet to be 
addressed.  It is known, for example, that although several tumors have been found to 
express the EGFRvIII mutation, cells within these cancers often exhibit significant 
antigenic heterogeneity.  In addition, a major mechanism by which tumors have been 
shown to evade the immune system is through the process of immune editing, whereby 
tumor cells are selected for the ability to either mutate or down-regulate a targeted 
antigen of interest.  Both of these phenomena likely contributed to observations in 
clinical studies of the EGFRvIII peptide vaccine, in which multiple patients achieved 
significant survival benefits but eventually recurred owing to the outgrowth of EGFRvIII 
antigen-loss variant tumors (Sampson et al., 2010).  Unlike the EGFRvIII vaccine, which 
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was found to elicit a predominantly humoral immune response, strategies designed to 
promote EGFRvIII-targeted T-cell immunity in particular may actually address these 
therapeutic shortcomings.  For instance, T-cell responses have been shown to mediate 
endogenous priming associated with epitope spreading (Pilon et al., 2003), and are also 
capable of protecting against antigen loss through direct bystander effects (Zhang et al., 
2008).  Given that recent clinical studies have associated favorable clinical responses 
with the ability to produce broad immunity to previously untargeted antigenic 
determinants (Corbiere et al., 2011), further study regarding the ability for T-cell based 
antitumor therapy to elicit these responses should be an emerging priority.  
The following chapter will review in detail a particularly promising approach 
that seeks to harness the cytotoxic T-cell immune response against tumors through 
bispecific antibodies.   
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2 Bispecific Antibodies Engage T cells for Antitumor 
Immunotherapy 
Although considerable evidence supports that T cells play a critical role in the 
immune response against cancer, the ability to mount and sustain tumor-specific cellular 
responses in vivo remains a challenge.  A novel strategy that harnesses the cytotoxic 
advantage of T cell therapy is the use of bispecific antibodies designed to engage and 
activate endogenous polyclonal T cell populations via the CD3 complex, but only in the 
presence of a tumor antigen.  Although antibody constructs with dual specificity were 
first described as anticancer therapeutics over 25 years ago, it was not until recently that 
one subclass of bispecific single-chain antibody, the bispecific T cell engager (BiTE), 
emerged as superior to previous iterations in achieving efficacy in both animal models 
and early clinical trials.   
This chapter details the evolution of bispecific antibodies in antitumor 
immunotherapy, including insights as to their mechanism of action and data that 
support the BiTE platform as a therapeutic model with great potential in the treatment 
of malignant disease.  Included will be a discussion regarding the greatest hurdles 
impeding further clinical translation of bispecific antibodies, specifically in the context of 
immunoprivileged sites as is the case for intracerebral malignancies. 
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2.1 Introduction to T-Cell Therapy for Cancer 
Perhaps one of the clearest pieces of evidence in support of cellular-based cancer 
therapy is in the treatment of hematological malignancies such as leukemia and multiple 
myeloma, wherein individuals who relapsed after initial therapy with hemopoietic stem 
cell transplantation (HSCT) have ultimately achieved complete remission upon 
allogeneic infusion with unmanipulated donor lymphocytes (Dazzi et al., 2000, Lokhorst 
et al., 2000).  In addition, following HSCT, positive clinical outcomes have been 
associated with the development of antigen-specific T cells reactive against either minor 
histocompatibility (Nishida et al., 2009) or tumor-associated antigens (Rezvani et al., 
2007) in what has been described as a complex graft-versus-leukemia interaction 
(Sprangers et al., 2007, Kolb, 2008).  While antitumor responses in this system are largely 
attributed to partial HLA-mismatch between donor and patient, these findings 
corroborate that under appropriate conditions, cellular immunity may be redirected 
therapeutically against neoplasms with remarkable efficacy.   
In that vein, it has been established that—much like antibodies—T cells 
successfully penetrate deep tissue beds and target tumor antigen deposits therein with 
great specificity.  Indeed, high densities of CD8+ effector memory T cells have been 
isolated from tumor parenchyma in patients with colon cancer (Pages et al., 2005, Galon 
et al., 2006) and non-Hodgkin lymphoma (NHL) (Wahlin et al., 2007); moreover, the 
quantities of tumor infiltrating lymphocytes (TILs) were shown to predict increases in 
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overall survival, supporting the idea that these cell populations could be sequestered 
and then infused therapeutically.  To that end, and as first described in a seminal paper 
by Rosenberg and colleagues in 1988 (Rosenberg et al., 1988), the adoptive transfer of 
autologous T cells derived from TIL isolates has demonstrated substantial clinical 
relevance, in one study leading to objective responses of up to 70% in patients with 
refractory metastatic melanoma (Dudley et al., 2005, Dudley et al., 2008).   
With the hope of enhancing the efficacy of what already appears to be a potent T 
cell therapy, currently in development is the ability to engineer a patient’s primary T 
cells with a second T cell receptor (TCR) of known specificity for a defined tumor 
antigen (Coccoris et al., 2005); early results from clinical studies of transgenic TCR 
technology confirm that this strategy may feasibly redirect and activate T cells against 
tumor antigens (Duval et al., 2006).  Based on similar principles, T cells have also been 
modified to express synthetic chimeric antigen receptors (CARs) which consist of an 
extracellular single chain variable fragment (scFv) derived from a tumor-reactive 
monoclonal antibody, fused to an intracellular CD3  chain signaling domain (Cartellieri 
et al., 2010), thereby endowing T cells with expansive reactive capabilities that span 
what would otherwise be physiologically exclusive to the humoral repertoire.  Although 
it remains unclear whether T cell modifications such as transgenic TCRs and CARs will 
ultimately realize widespread clinical success, these advancements in adoptive therapy 
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continue to show promise in early clinical trials, supporting the general notion that T 
cells are indeed critical mediators in an effective antitumor immune response.    
2.1.1 Updates on Chimeric Antigen Receptor Therapy 
Chimeric antigen receptors (CARs) represent a versatile class of receptors that 
are generated by combining the variable region of an antibody with a T-cell signaling 
molecule, usually CD3 (Gross et al., 1989).  Because their capacity for antigen recognition 
is derived from antibody binding, CARs have the ability to mimic endogenous TCR-
mediated activation, without the need for classical MHC restriction.  Moreover, whereas 
physiological TCRs are restricted by thymic selection, antibody-redirected CARs can 
accommodate virtually infinite antigenic diversity and operate at affinities even in the 
nanomolar range (Hollyman et al., 2009, Lamers et al., 2006). 
An additional advantage of the CAR platform is the incorporation of 
costimulatory molecules such as CD28 and 4-1BB into the CD3 signaling domain to 
improve T-cell expansion, survival, cytokine secretion and tumor lysis (Milone et al., 
2009, Zhao et al., 2009, Zhong et al., 2010).  Clinical trials utilizing these second and third 
generation CARs have now targeted a variety of antigens and malignancies and have 
demonstrated their remarkable potential (Pule et al., 2008, Kochenderfer et al., 2012, 
Porter et al., 2011, Brentjens et al., 2011).  However, severe adverse events and even 
patient deaths have occurred when these CARs have been directed against antigens 
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shared by normal tissues including CD19 and ERBB2 (Morgan et al., 2010, Brentjens et 
al., 2010).    
2.2 Current Challenges for T-Cell Antitumor Responses 
Despite their success to date, T cell-based therapies as they presently exist are 
limited by a number of conceivable drawbacks.  First, adoptive cell transfer (ACT) is by 
nature highly personalized and thus labor-intensive, requiring that laboratories not only 
possess an extraordinary level of expertise, but also that they create essentially new 
reagents for each patient who is to receive treatment.  Furthermore, besides melanoma, 
few cancers have been shown to naturally give rise to tumor-reactive lymphocytes that 
can be isolated and productively expanded in every eligible patient, bringing into 
question the practicality of applying ACT across variegated clinical scenarios.   
Perhaps the most discouraging aspect of ACT, however, lies in its fundamental 
dependence on the in vivo maintenance of infused T cell populations.  The 
immunological processes that regulate survival and proliferation of engrafted 
lymphocytes are complex and tightly controlled, though this balance is often highly 
dysregulated in a typical cancer patient.  Late-stage tumors in particular exhibit a 
number of evasive mechanisms that antagonize the development of an optimal cellular 
response; during a process known as immunoediting, cancer cells are hypothesized to 
undergo Darwinian-like selection for characteristics that obstruct T cell reactivity, such 
as downregulation of co-stimulatory molecules, MHC, and other factors closely 
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associated with antigen presentation (Marincola et al., 2000, Meidenbauer et al., 2004).  
Tumors are also known to alter earlier events in antigen processing, as evidenced by 
their derangement of normal proteasomal machinery (Seliger et al., 2000, Gobbi et al., 
2004, Hayashi and Faustman, 2002), loss of intracellular peptide transporters (Johnsen et 
al., 1999, Ritz et al., 2001), or inactivation of 2-microglobulin protein (Cabrera et al., 
2003), a necessary component for transport of MHC class I to the cell surface.   
Regardless of the precise mechanism, one consequence of immune escape is that 
tumor-specific lymphocytes, even those with highly avid, genetically modified TCRs, 
will not receive adequate stimuli to be activated or sustained in vivo.  It has been 
demonstrated, for instance, that without appropriate co-stimulation signals, first-
generation CAR-transduced T cells fail to proliferate and survive following infusion, 
leading to only modest results in early clinical trials (Kershaw et al., 2006, Lamers et al., 
2006, Till et al., 2008).  To address this issue, the latest CARs have been modified to 
incorporate additional pro-immunomodulatory signaling endodomains from 
costimulatory molecules like CD28 and CD137 (Cartellieri et al., 2010, Zhao et al., 2009).  
While such second- and third-generation constructs have yet to be validated in clinical 
trials, it has already been forewarned that expression of manifold signaling moieties 
within a single lymphocyte clone may excessively reduce the threshold of activation, 
leading to increased risk for autoimmune toxicity. 
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Indeed, potentially devastating effects associated with non-specific lymphocyte 
activation have been clearly illustrated in the early discontinuation of a clinical trial 
studying TGN1412, a humanized anti-CD28 superantagonistic monoclonal antibody 
uniquely designed to activate T cells without the need for concomitant TCR engagement 
(Suntharalingam et al., 2006).  Immediately after intravenous infusion with TGN1412, all 
six study participants experienced severe cytokine storm and were admitted to intensive 
care for multisystem organ failure.  While multiple factors may have ultimately 
contributed to these disastrous outcomes, the magnitude of systemic toxicities observed 
in this setting reaffirms the critical importance of maintaining targeted specificity.     
The overall challenge, then, is to develop safer, more specific and more effective 
antitumor therapies that not only exploit the cytotoxic potential of the cellular immune 
response and circumvent mechanisms of tumor evasion, but are also manufactured with 
relative ease and possess broad applicability across clinical scenarios.  To these ends, the 
bispecific antibody therapeutic platform represents a promising approach, as it has been 
shown to successfully engage and activate endogenous polyclonal T cells via the TCR-
CD3 complex, exclusively in the presence of a tumor antigen.   
2.3 The History and Development of Bispecific Antibodies 
Bispecific antibodies were first developed upon previously established principles 
of monoclonal antibody therapy—namely that, in the treatment of malignant diseases, 
antibodies had already been shown to possess the specificity necessary to mediate a 
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number of antigen-specific immune mechanisms.  Native antibodies of the 
immunoglobulin G (IgG) type for example are made up of two identical, antigen-
binding, variable regions joined by a constant fragment domain (Fc).  Monocytes and 
other phagocytic cells bind Fc domains via their surface Fc receptors, resulting in 
specific lysis of targeted cells through a well-characterized antibody-dependent cell-
mediated cytotoxicity (ADCC) mechanism.  Besides interacting with cellular effectors 
however, antibodies also recruit endogenous proteins of the complement cascade, or 
alternatively, they can be artificially modified to deliver a payload of cytotoxic 
molecules including radioisotopes (Wiseman et al., 2002, Zelenetz, 2003), 
chemotherapies (Sievers et al., 2001), or bacterial toxins (Oh et al., 2009) to tumors with 
great specificity.   
Like armed monoclonal antibodies, bispecific antibodies do not occur naturally 
in the human body and must be created using either recombinant DNA or cell-fusion 
technologies.  These techniques make it possible to combine multiple humoral 
specificities into a single molecule while retaining the specificity—and occasionally the 
function—of each component contributing to its overall design.  Thus, in the most 
general sense, the term “bispecific antibody” refers to a class of constructs in which two 
antibody-derived antigen-specific binding sites are aligned within one molecule.  In the 
context of tumor immunotherapy, this typically means that one arm of the construct is 
specific for an epitope on the surface of a cancer cell (target-binding arm), while the 
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other arm is specific for the effector cell (effector-binding arm).  The theoretical benefit of 
this divalent design lies in its potential to simultaneously redirect and locally activate 
cellular effectors in the presence of cancer cells, thereby maximizing proximate target 
lysis while minimizing non-specific cytotoxicity in surrounding healthy cells and tissues.   
The concept of using bispecific antibodies to activate T cells against tumor 
antigen was first described over 20 years ago (Perez et al., 1985, Staerz et al., 1985).  
Among the first formats pursued were constructs designed to bind the monomorphic 
TCR-CD3 complex, a strategy that offers a number of conceivable advantages.  
Triggering lysis by this approach allows bispecific antibodies to interact globally with 
the T cell compartment, thereby circumventing the restriction of clonotypic specificity 
and proliferation.  In addition, because the target-binding arm is derived at least in part 
from the variable portion of a tumor-specific antibody, the overall effect is not only 
highly specific, but also widely applicable against a broad array of antigens—that is, 
antibodies possess the ability to bind tumor epitopes beyond the MHC-peptide 
complexes classically recognized by TCR.  As a result, bispecific antibodies both increase 
the complement of targetable T cell antigens and also overcome mechanisms of tumor 
immune escape such as loss or downregulation of MHC.   
To date, technical aspects of producing bispecific antibody constructs at a 
clinically relevant quantity and purity have proven challenging.  As a result, a wide 
variety of formats based on the same functional principle have been pursued; these 
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include diabodies, tandem scFv, cross-linked antigen binding fragments (Fab), and 
quadroma-derived constructs.  
 
Figure 4:  Bispecific antibody formats. 
(a) Quadroma-derived bispecific antibody, resembling monospecific monoclonal 
antibodies in structure and size. (b–d) Heterodimeric bispecific antibodies of medium 
size, comprising constant immunoglobulin regions and/or heterodimerization domains. 
(e–f) Bispecific antibodies of minimal size, consisting only of variable immunoglobulin 
regions. Abbreviations: CH1–3, constant regions of Ig-heavy chain; CL, constant regions of 
Ig-light chain; Fab, antigen binding fragment; Fc, constant fragment; VH, variable region 
of Ig-heavy chain; VL, variable region of Ig-light chain. The difference in colors (i.e. gray 
and purple) represents different binding specificities.  Figure reproduced with 
permission (Kufer et al., 2004). 
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The first attempt to produce antibodies with dual specificity employed 
quadroma technology, which relies on the fusion of two distinct hybridomas expressing 
monoclonal antibodies of desired specificity (Staerz and Bevan, 1986, Milstein and 
Cuello, 1983, Suresh et al., 1986).  Within these hybrid-hybridomas, bispecific antibodies 
are produced through the random pairing of immunoglobulin (Ig) heavy and light 
chains.  Because unfunctional, mispaired byproducts often result during this process 
and subsequently confound purification, more recent methods have been developed to 
employ antibody chains selected for their tendency to couple with each other 
preferentially (Lindhofer et al., 1995).  Structurally, quadroma-derived bispecific 
antibodies resemble conventional antibodies; however, in order to avoid the potentially 
undesirable or unpredictable effects of an intact constant region, the Fc domain may be 
cleaved away enzymatically, leaving behind paired Fab fragments with distinct antigen 
specificity (Mezzanzanica et al., 1988).   
Similar divalent constructs have been produced without the use of quadroma 
technology, either by site-directed chemical cross-linking between two Fab fragments at 
hinge cysteine residues (Glennie et al., 1987), or by various recombinant DNA strategies 
that introduce moieties designed to promote favorable pairing via specific inter-protein 
interactions.  For example, in order to optimize heterodimer formation and reduce 
mispairing events, constant fragments of individual chains can be mutated to express 
adhesive amino acid sequences (Merchant et al., 1998), and in some cases modified or 
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completely replaced with complementary proteins pairs (e.g. Fos and Jun, or Ig domains 
C and CH1) that exhibit natural tendencies to associate as heterodimers (Kostelny et al., 
1992, Muller et al., 1998, de Kruif and Logtenberg, 1996).   
Among the smallest bispecific antibody constructs are diabodies and tandem 
scFvs, both of which represent unique combinations and orientations of antibody 
variable domains (VH and VL) within a single molecule.  The basic diabody structure 
consists of two separate single chain fusion products held together by non-covalent 
interactions.  Each single chain contains one VH and one VL domain with opposing 
specificities (Holliger et al., 1993, Holliger et al., 1996).  When co-expressed in bacteria, 
independent single chains combine with each other to form stable hybrid bispecific 
diabody heterodimers.  However, as a pairing byproduct, it is again possible to produce 
an inactive homodimer; thus, in order to improve overall stability as well as purity, 
tandem diabodies were designed, in which all four variable domains are translated as a 
single chain molecule (Kipriyanov et al., 1999).      There still exists a theoretical concern, 
however, that inherent to the diabody approach is a structural and steric limitation 
related to the number of amino acid linkers connecting antigen-binding arms.  Whereas 
diabodies contain two separate linkers between each arm, bispecific tandem scFv 
molecules, by contrast, include only one flexible glycine-serine linker between native 
scFv domains.  In other words, tandem scFvs possess two binding sites that can rotate 
freely relative to each other, offering conceivable advantages in settings where antigen 
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epitopes of interest have limited accessibility on different cell surfaces.  Like diabodies, 
production of tandem scFvs was also first attempted in Escherichia coli systems 
(Mallender and Voss, 1994, Gruber et al., 1994), though studies would reveal that 
bacterial expression for bispecific tandem scFv was unreliable (Kipriyanov et al., 2003), 
and that yields of functional product remained poor following renaturation of proteins 
isolated from inclusion bodies.  This issue, however, was largely addressed after 
establishing that mammalian cells (Schlatter et al., 2005) could be used to manufacture 
bispecific tandem scFvs with relative ease (Birch and Racher, 2006), since the proteins 
are secreted directly into culture media in functional, folded conformations (Mack et al., 
1995).   
To date, few studies have presented thorough comparative analyses between 
tandem diabody and scFv formats.  Early evidence suggests that tandem diabodies may 
exhibit increased stability due to their tightly packed variable domains, though as 
previously mentioned, this conformation conversely restricts mobility at the linker 
region.  In a recent report, both types of tandem bispecific antibody demonstrated 
indistinguishable binding kinetics and biological activity in vitro when targeting 
carcinoembryonic antigen-expressing tumor cells (Korn et al., 2004).  Other groups have 
shown that conversion from preexisting diabody constructs to tandem scFv may 
drastically increase cytotoxic function (Asano et al., 2011).  Additional studies are 
necessary to corroborate these observations in vivo and multiple factors will ultimately 
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dictate whether either format will translate more successfully into the clinic.      Perhaps 
the relative dearth of literature contrasting the therapeutic potential of what may at first 
appear to be largely synonymous antibody-derived conjugates and fragments reflects 
the rapidity with which several antibody-modifying technologies have become available 
and subsequently cultivated by the pharmaceutical industry.  As such, more than ten of 
the largest pharma companies have either developed or licensed a unique variant of the 
bispecific antibody theme, and a timely review of selected initiatives has been published 
elsewhere (Moran, 2011).  Notably, early preclinical data suggests that one platform in 
particular, the dual-affinity re-targeting (DART) molecule—distinguished by the 
addition of a proprietary covalent linkage between VH domains—may improve upon the 
stability and potency realized by previous diabody and scFv formats (Moore et al., 
2011).  
2.4 Clinical Experience with Bispecific Antibodies 
While a vast majority of bispecific antibodies have been developed to activate T 
cells against tumor-associated antigens, efforts have also been made to redirect other 
cellular effectors of the immune system for targeted cytolysis.  Among myeloid cells, 
monocytes and neutrophils have been shown to mediate antitumor effects when 
triggered by chemically linked F(ab’)2 bispecific antibodies through either CD64 (James 
et al., 2001) or CD89 (Deo et al., 1998) activation signaling, respectively.  Limited clinical 
efficacy has been reported to date on these constructs, though this might be explained by 
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the fact that corresponding preclinical studies required extremely high effector-to-target 
(E:T) ratios (up to 200:1), high concentrations of the therapeutic agent (from 0.1 to 1 g 
ml-1), and in one case prestimulation of effector cells with IFN, in order to achieve 
acceptable efficacy. 
A number of notable quadroma-derived bispecific antibody constructs have been 
created and tested for their ability to engage natural killer (NK) cells via CD16 in the 
presence of Her2/neu- and CD30-expressing tumors (Weiner et al., 1995, Hartmann et 
al., 1997).  In what is perhaps the first study establishing clinical proof for the bispecific 
antibody concept, treatment with a CD16-activating F(ab’)2 that targets CD30 in patients 
with Hodgkin’s disease was shown to lead to objective antitumor responses in 25% of 
patients, including one documented complete remission and three partial remissions 
(Hartmann et al., 2001).  While initial study results showed promise, it is important to 
note that these trials ultimately had to be halted due to inadequate production of clinical 
test material.   
As previously mentioned, in order to redirect and activate T cells—particularly 
CTLs—against tumors, the most popular approach by far is triggering via the TCR-
associated CD3 complex.  Under normal physiological conditions, stimulation of T cell 
activity occurs through a series of fundamental processes regulated by several 
molecules; traditionally, a first signal is provided by TCR engagement with peptide-
MHC, and a second signal arises from interactions with costimulatory molecules on the 
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surface of the T cell, including CD28.  Therefore, it was not surprising to discover that, at 
first, most CD3-directed bispecific F(ab’)2 antibodies and recombinant diabodies 
demonstrated a strict requirement for lymphocyte preconditioning or costimulation in 
order to elicit significant lysis against tumor cells both in vitro and in animal models 
(Demanet et al., 1996, Titus et al., 1987, Weiner and Hillstrom, 1991, Renner et al., 1994, 
Kipriyanov et al., 1998, Zhu et al., 1996, Cochlovius et al., 2000).  In addition, until the 
advent of tandem scFv formats, it was unclear whether systemic therapy with CD3-
engaging bispecific antibodies could feasibly treat metastatic disease, given that 
previous efforts to administer constructs intravenously required excessive dosing and 
resulted in prohibitive autoimmune toxicity (Kroesen et al., 1994, De Gast et al., 1995). 
Consequently, while bispecific antibodies in general tout an extensive history, 
even the most potently activating molecules developed to date have been thwarted by 
several shortcomings, among which include an inability to produce the drug sufficient 
quantities, an apparent need for T cell costimulation, and a risk of limiting side-effects at 
high doses.   
Promising to deliver where previous iterations have fallen short, however, is a 
new subclass of recombinant bispecific tandem scFv referred to as the bispecific T cell 
engager (BiTE).  Because of its recent success in animal models and early clinical trials, 
the BiTE format has rekindled great interest in the overall development of antibody-
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directed, antitumor T cell therapies, and may offer wide applications across multiple 
human cancers in upcoming years. 
2.5 Bispecific T-Cell Engagers Redirect Cellular Immunity 
Against Cancer 
Among the hundreds of relatively unsuccessful bispecific antibody designs, 
BiTEs have emerged as superior to other formats; they are relatively stable and easy to 
produce in mammalian cells, are extremely potent at low doses, and are able to mediate 
cytotoxicity in the absence of supplemental lymphocyte stimulation (Loffler et al., 2000, 
Kufer et al., 1997, Mack et al., 1997, Mack et al., 1995).  Generally, BiTEs are polypeptides 
consisting of two scFvs in tandem with total molecular weights ranging from 55 to 60 
kDa; by definition, while their effector-binding arms bind specifically to the epsilon 
subunit of CD3, their opposing target-binding arms can be directed against any number 
of epitopes, such as those differentially expressed on the surface of a tumor cell. 
In lymphoma, one prominent, well-characterized BiTE is the recombinant 
bscCD19xCD3 construct, targeting the pan B-cell antigen, CD19 (Bargou et al., 2008).  
Human xenograft murine models, in which severe combined immunodeficiency, non-
obese diabetic (NOD/SCID) mice are engrafted with human T-cells and tumor cells, have 
been used extensively to study the activity of the bscCD19xCD3 BiTE in vivo with 
remarkable results; treatment prevented growth of subcutaneous human B lymphoma 
xenografts and in some cases even cured animals with early stage tumors (Dreier et al., 
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2003).  Using the same murine model, another group of successful studies examined the 
efficacy of BiTEs directed against EpCAM (Schlereth et al., 2006, Brischwein et al., 2006), 
an epithelial cell adhesion molecule overexpressed in both colon and ovarian cancers.  
Additional tumor antigens that are currently being investigated as targets for BiTE 
therapy include Her2/neu, EGFR, CEA, CD33, EphA2, and MCSP (Baeuerle and 
Reinhardt, 2009).   
Most recently, translation to human trials assessing the clinical activity of the 
bscCD19xCD3 construct in patients with non-Hodgkin’s lymphoma have confirmed its 
remarkable potency (Bargou et al., 2008, Handgretinger et al., 2011).  All seven patients 
in the study who received continuous infusion with BiTE at 0.06 mg/m2 per day showed 
objective tumor regression, including five partial responses and two complete responses 
with clearance of tumor from the blood, bone marrow, and liver.  This drug dose 
produced serum levels five orders of magnitude lower than reported effective doses of 
the CD19-specific standard-of-care, rituximab.  
Notably, no dose-limiting cytokine release syndrome was evident in this trial.  
Although CNS side effects did occur (e.g., confusion, tremor, focal neurologic deficits 
and seizures) they were all fully reversible.  Similarly, autoimmune phenomena were 
generally absent; however treatment with the bscCD19xCD3 BiTE led to nearly complete 
depletion of CD19-expressing normal B-cells.  
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The second BiTE construct that has been tested in clinical trials is MT110, 
designed to target EpCAM on a wide array of solid tumors in patients with lung, gastric, 
and colorectal cancers.  Early phase I study results demonstrated disease stabilization in 
7 of 19 evaluable patients following infusion with clinically-tolerated low doses of 
MT110, and evaluation of the therapy at higher doses is ongoing (Fiedler, 2009).   
2.6 Mechanistic Studies of BiTE-Mediated Antitumor Immunity 
Part of the reason why it is thought that BiTEs so potently mediate T cell 
activation is that, on a cellular level, they have been shown to induce immunological 
synapses between CD8+ T cells and tumor cells that are indistinguishable in composition, 
size, and subdomain arrangement from native cytolytic synapses (Offner et al., 2006).  
Following antigen-specific BiTE-mediated activation, apoptosis occurs via perforin-
mediated membrane disruption, followed by influx of various granzyme proteases 
(Haas et al., 2009).  Also, T cells begin to proliferate, secrete characteristic cytokines, 
including TNF, IFN, IL-6, IL-2, IL-4 and IL-10, and express surface markers that 
indicate activation such as CD69 and CD25.  While proliferation in response to BiTE 
activation is most obvious in the CD8+ T cell compartment, CD4+ cells are also known to 
respond by dramatically upregulating expression of granzyme B (Mack et al., 1997), a 
critical protein involved in the apoptotic process. 
BiTE proteins have the ability to initiate lytic synapses in the presence of tumor 
antigen, and experiments have demonstrated that robust T cell responses are possible 
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even against tumor cells that do not express MHC class I.  Interestingly, BiTEs have also 
been shown to reactivate potentially unresponsive T cells, effectively redirecting TIL 
populations to eradicate donor-matched xenotransplanted tumors in an 
immunocompromised mouse model (Miescher et al., 1986, Schlereth et al., 2005).   
One study using video-assisted microscopy showed that during the cytotoxic 
event, BiTE constructs transiently link T cells with tumor cells and sustain repeated 
rounds of serial target cell lysis at E:T ratios as low as 1:5 (Hoffmann et al., 2005).  These 
findings are consistent with the fact that, unlike previous bispecific antibody formats, 
BiTEs can trigger specific lysis at concentrations even in the low picomolar range (Dreier 
et al., 2002).  At the same time, BiTEs nevertheless display exquisite specificity; at 
concentrations several thousand-fold greater than their EC50 (2-1,000 pg/mL) (Baeuerle et 
al., 2009), BiTEs retain their specificity and will not trigger T cell activation unless 
presented with a substrate expressing the target antigen (Brischwein et al., 2007). 
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Figure 5:  Schematic summary of BiTE mechanism-of-action. 
 
2.7 Discussion for Chapters 1 and 2 
More than 100 years ago, Paul Ehrlich first suggested that the immune system 
could be redirected to recognize and eradicate tumors (Ehrlich, 1906), and since that 
time, parallel advances in both technology and our basic understanding of 
immunological principles have made it possible to manipulate the human immune 
system against cancer with unprecedented elegance.  
 When compared with alternative T cell-based therapies for cancer, BiTEs 
represent a unique approach in that they are fully antibody-derived and, as such, do not 
require the ex vivo enrichment and modification, nor the in vivo maintenance associated 
with antitumor therapies that rely on infused lymphocytes.  Moreover, BiTEs maintain 
the ability to mediate tumor lysis despite certain classical mechanisms of immune 
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escape, given that they interact with polyclonal T cells without requirements for MHC 
presentation or TCR specificity.  It has also been suggested that monovalent interactions 
between surface antigen and bispecific constructs are less likely to induce antigenic 
modulation than binding by parental monoclonal antibodies (Nolan and O'Kennedy, 
1990). 
In contrast to preceding bispecific antibody formats, BiTEs clearly possess 
multiple advantages that span across nearly all characteristics from structure to function.  
As previously mentioned, in the case of bscCD19xCD3, targeted lysis was potent enough 
such that global eradication of even normal CD19-expressing cells occurred.  Thus, 
perhaps one limitation to realizing the maximum therapeutic potential of the BiTE 
platform is a lack of tumor-specific targets that are both frequently and homogenously 
expressed in tumor tissue.  
Among the many mutations that often appear in tumor cells, the type I 
epidermal growth factor receptor (EGFR) is perhaps the most widely implicated.  As 
reviewed in Chapter 1 of this dissertation, one well-characterized mutant form of the 
receptor is the class III variant, EGFRvIII, a constitutively active, ligand-independent 
version of the wild-type receptor, first discovered in human glioblastoma (GBM) but 
subsequently identified in a wide variety of cancers.  Our group has extensive 
experience with EGFRvIII, which—because of its exclusive expression in tumor cells and 
complete absence from normal, healthy tissues—offers an ideal extracellular epitope for 
 59 
antibody-based therapies.  Until our studies, there have not been published studies of a 
BiTE designed to target the EGFRvIII antigen or any other tumor-specific antigen. 
 Because our laboratory focuses primarly on intracerebral malignancies and 
immunotherapy for glioma, we are intimately familiar with the challenges associated 
with administering therapeutic effector cells and molecules in the context of an intact 
blood brain barrier (BBB) and intratumoral pressures that might hinder drug diffusion 
or delivery.  A number of factors must be considered when addressing whether 
systemically administered treatments will reach a tumor within the brain.  While it is 
believed that, under normal physiological conditions, the BBB is poorly permeable to 
both antibodies and naïve T lymphocytes, it has long been established that in the 
presence of neuroinflammation, the BBB has diminished ability to block the migration of 
cells and proteins into the CNS (de Vries et al., 1997).  How this phenomenon will 
impact the ability for BiTEs to localize to an intracerebral tumor is currently unknown.  
Additionally, whether BiTEs will reactivate TILs within glioma tissue, or possibly 
facilitate trafficking of T cells from the periphery across the BBB, has yet to be studied.  
The potential inhibitory impact of intratumoral regulatory T cells will also need to be 
considered.  These questions in will be addressed by several experiments throughout the 
remainder of this dissertation. 
Despite burgeoning interest in bispecific antibodies and permutations thereof, 
the issues of stability and cost-effective production persist as major obstacles for those 
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who wish to ultimately advance this therapeutic platform.  Given that current clinical 
protocols for bispecific therapeutics inconveniently require continuous infusion over 
several weeks, as the field continues to mature, priorities will converge on molecular 
modifications that are designed to enhance half-life and maintenance at clinically 
relevant plasma concentrations.  Furthermore, the latest technologies designed to 
optimize production and reduce manufacturing costs of monoclonal antibodies and 
their derivatives in insect (Johansson et al., 2007) and mammalian cells may help to 
propel development of bispecific antibodies in upcoming years.   
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3 Generation of Tandem Single-Chain Variable 
Fragment Reagents for Bispecific Antibody 
Evaluation 
3.1 Introduction 
As reviewed in the preceding chapter, the term bispecific antibody can refer to 
any one of many antibody-based molecules that have the capacity to recognize two 
different antigens.  The BiTE platform is perhaps one of the most successful subclasses of 
bispecific antibody given that it has proven feasible to manufacture and administer on a 
large scale, sufficient at least for early translation in clinical trials.  Despite this success, 
the ability to efficiently produce bispecific antibody reagents in general remains a 
paramount challenge in the field (Kufer et al., 2004).   
Among the most popular formats for bispecific antibodies are diabodies and 
tandem scFv, the latter of which is essentially synonymous with BiTE.  Both the diabody 
format and the tandem scFv molecule have recently become popularized owing to their 
small size and relative ease of manipulation using standard recombinant technologies.  
In the case of diabodies, another advantage is their ability to be produced at large 
quantities in bacterial expression systems.  To date, there has been limited experience 
producing tandem scFv molecules in bacterial expression systems like Escherichia coli, 
and it appears that, unlike diabodies, several groups have reported difficulty refolding 
tandem scFv molecules from insoluble inclusion bodies, specifically due to the 
unpredictable fashion by which variable domains fold and associate with each other in 
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solution (Kipriyanov et al., 2003, Mallender and Voss, 1994, Gruber et al., 1994).  
Notably, because tandem scFvs typically possess four variable domains, these molecules 
have the added option of folding either between adjacent domains or head-to-toe, much 
like what has been described elsewhere for the bispecific single chain diabody.   
In the following sections we will introduce our design for the EGFRvIII-specific 
BiTE.  In addition, despite the known challenges of producing functional tandem scFv 
molecules in bacterial systems, we will demonstrate the efficient expression and 
purification of several bispecific antibodies of the BiTE subclass, which will serve as the 
basis for reagents utilized throughout the remainder of this dissertation. 
3.2 Materials and Methods 
3.2.1 Construction and Expression of cDNA Encoding 
bscEGFRvIIIxCD3 
Synthesis of cDNA encoding bscEGFRvIIIxCD3 was carried out using standard 
recombinant technologies.  The scFv directed against EGFRvIII was isolated from pMR1-
1(scFv) (Kuan et al., 1999), and the scFv specific for human CD3 was derived from the 
hybridoma cell line, OKT3, by previously described methods (Arakawa et al., 1996).  A 
hexahistidine-tag was added to the carboxyl terminus to aid in the detection and 
purification of the final protein product.  To obtain the bscEGFRvIIIxCD3-encoding 
DNA, overlapping PCR was performed with primers MR1-1 FW, MR1-1 RV, OKT3 scFv 
FW and OKT3scFv RV.  With a linker sequence at the 3’ of MR1-1 and the 5’ of OKT3 
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scFv, the two scFvs can be annealed together using the MR1-1 FW and OKT3 scFv RV 
primers.   
Table 3:  Primers designed to introduce a flexible linker and construct 
bscEGFRvIIIxCD3 by overlapping PCR. 
Designation Sequence 
MR1-1 FW CGATCATATGGCCATGGCCCAG GTGAAACTGCAGCAGTCT 
MR1-1 RV AGACTGCTGCAGCTGGACCTGTGAACCGCCACC 
ACCTTTGATTTCCAGCTTGGTGCCATC 
OKT3 scFv FW GATGGCACCAAGCTGGAAATCAAAGGTGGTGGCGGTTCAC 
AGGTCCAGCTGCAGCAGTCT 
OKT3 scFv RV CAGTGAATTCTTAGTGGTGATGGTGATGATGGTTTATTTCC 
AACTTTGTCCCCGA 
 
 
Figure 6:  Schema of MR1-1xOKT3 (cDNA for bscEGFRvIIIxCD3) design. 
 
The PCR product was analyzed on a standard agarose-gel system and purified 
according to manufacturer’s instructions (QIAquick Gel Extraction Kit, QIAGEN).   The 
resulting gene was cloned into pGEM-T Easy vector (Promega) sequenced and 
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subcloned into the expression vector, pRB199 (Kuan et al., 2000) via NdeI and EcoRI 
restriction sites.     
 
Figure 7:  cDNA and deduced amino acid sequence of the murine EGFRvIII BiTE 
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3.2.2 Expression and Isolation of Insoluble Inclusion Bodies 
Bispecific antibody-encoding cDNA in pRB199 was transformed into E. coli strain 
BL21(λDE3).  Bacterial cultures were inoculated into Terrific Broth Complete (Teknova) 
containing 80 μg/mL chloramphenicol and grown at 37 °C to an A600 of 2.0.  To prepare 
culture media, 1 mL of a stock chloramphenicol solution was added to each liter of 
Terrific Broth Complete, along with 20 mL of 20% glucose solution and 4.1 mL of a 1 M 
MgSO4 solution.  Prepared media was divided equally into six 2 L flasks (500 mL per 2 
L flask).  Expression of the recombinant bispecific antibody was induced with 0.1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) at 37 °C for 4 hours.  Cultures were 
centrifuged and bacterial pellets were resuspended in a buffer containing 50 mM Tris, 
pH 7.5, 20 mM EDTA (TE50/20) for storage at -70 °C. Inclusion bodies were prepared by 
extensively washing bacterial material with TE 50/20. 
Table 4:  Protocol for expression of bispecific antibodies in insoluble inclusion bodies 
Step Comments 
Scrape bacteria into prepared broth. May start with a seed culture of 50 
mL prior to distributing equally 
among six 2 L flasks. 
Incubate at 37 ⁰C with shaking at 250 rpm until 
OD600 = 1 to 1.5.   
~ 8 hours. 
Add IPTG to a final concentration of 1 mM.  
Continue incubation between 90 minutes and 4 
hours, but not overnight. 
 
Centrifuge culture at 3500 rpm for 15 minutes at 
4 ⁰C. 
Can freeze pellet after this step or 
continue with protocol.  A 
freeze/thaw may help with lysis. 
Resuspend cells in 810 mL TE50/20 with a TE50/20:  50 mM Tris, pH 7.5, 20 mM 
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tissumizer and divide into six 250 mL bottles for 
a Sorval GSA rotor.   
EDTA.  Each bottle contains about 
135 mL. 
Incubate with shaking at room temperature for 
30 minutes. 
 
Add 10 mL (per L) of 5 mg/mL stock solution of 
lysozyme in H2O to the resuspension. 
 
Incubate 30 minutes with shaking.  
Add 15 mL of 5 M NaCl.  
Add 15 mL of 25% Triton X-100.  
Tissumize and incubate for 30 minutes at room 
temperature with frequent shaking. 
 
Centrifuge at 11,000 rpm for 50 minutes at 4 ⁰C. At this step, save the supernatant to 
ensure that the Triton X-100 solution 
did not remove the protein of 
interest. 
Resuspend pellet in 1% Triton X-100 in TE50/20 
(135 mL per bottle) with a tissuemizer. 
Pellet should be a white stripe on the 
side of the bottle. 
Centrifuge at 11,000 rpm for 40 minutes.  
Discard supernatant. 
 
Repeat wash three times but using only TE50/20 
(no triton). 
Can store inclusion bodies at -70 ⁰C 
or continue on to solubilizing steps. 
 
3.2.3 Solubilizing and Refolding Bispecific Antibodies 
IBs were solubilized in 6 M guanidine-HCl, reduced with dithioerythritol, and 
then refolded by 100-fold dilution into renaturation buffer (0.1 M Tris, 0.5 M arginine-
HCl, 0.9 mM oxidized glutathione, 2 mM EDTA, pH 10.3) at 4 °C with rapid mixing, 
followed by incubation at 4 °C for 72 hours.  After renaturation, the solution was 
dialyzed 3:50 against 0.1 M Tris, 0.5 M NaCl three times and filtered (0.2 μm) to prepare 
for metal ion affinity chromatography. 
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Table 5:   Protocol for solubilizing and refolding bispecific antibody from insoluble 
inclusion bodies. 
Step Comments 
Resuspend pellet in a solubilization buffer and 
tissuemize. 
In this case, 8 M Guanidine HCl, 100 
mM Tris pH 7.5 works well.  Start 
with 10 mL and add more buffer 
until ~90% solubilized. 
Incubate and shake at room temperature for 2 
hours. 
Can incubate overnight if desired. 
Spin down at 15,000-18,000 rpm to pellet 
unsolubilized inclusion bodies.  Save only 
supernatant. 
 
Determine protein concentration.   Can be performed with standard 
Bradford assay technique. 
Dilute the protein to 10 mg/mL using 
solubilizing buffer 
 
At dithioerythritol to a final concentration of 65 
mM (10 mg/mL).   
Usually one round of reducing is 
performed with 300 mg protein.   
Prepare 3 L refolding buffer and chill to 4 ⁰C. Refolding buffer:  0.1 M Tris pH 8.0, 
0.5 M L-Arginine-HCl (105 g/L), 0.9 
mM GSSG glutathione, oxidized (0.55 
g/L), and 2 mM EDTA. 
Adjust the buffer to pH 10.3 by adding NaOH. ~20 g NaOH per L. 
Add 10 mL of reduced, solubilized protein to 
one liter of chilled refolding buffer. 
Add protein while buffer is rapidly 
stirring in a continuous flow of 
approximately 10 mL per 20 seconds, 
with a pipette. 
Incubate solution at 10 ⁰C for at least 72 hours.  
Dialyze solution 3 L against 50 L in a buffer 
suitable for method of purification. 
In this case, 0.5 M NaCl, 0.1 M Tris 
pH 8.0.   
 
3.2.4 Purification of Bispecific Antibodies by Metal Affinity 
Chromatography 
Refolded bispecific antibody was purified by fast protein liquid chromatography 
(BioLogic DuoFlow 10 System; Bio-Rad) using TALON metal affinity resin (Clontech).  
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Briefly, sample was loaded by constant controlled flow at 2 mL/min and then the 
coluμmn was washed with 0.1 M Tris, 0.5 M NaCl until the 280 nm absorbance of the 
eluate returned to 0.  Protein was eluted by stepwise imidazole gradient at a flow rate of 
1 mL/min.  The product was concentrated with 10,000 MWCO columns (Sartorius 
Stedim), dialyzed against PBS, and sterile filtered.  Concentrations were determined by 
Bradford assay.  The product was subjected to SDS-PAGE analysis (2 µg of total protein 
per lane) under reducing conditions for purity by silver stain.   
3.2.5 Western Blot Analysis 
Following manufacturer instructions, proteins were transferred to membranes 
and incubated with anti-his(C-term) antibody-HRP (Invitrogen) at a 1:5000 dilution in 
PBS containing 0.05% Tween-20 and 5% nonfat, dry milk. Protein was then detected 
using SuperSignal West Femto Substrate (Thermo Scientific). 
3.2.6 Surface Plasmon Resonance 
Binding to antigen was measured by surface plasmon resonance (Karlsson et al., 
1991) using the GE Healthcare BIAcore 3000. Antigen was coupled to the surface of 
carboxylated dextran-coated CM5 research grade chips at pH 4.0 using the amide 
coupling reagents provided with the BIAcore system. Solutions of bscEGFRvIIIxCD3 
(100 nM, 200 nM, and 300 nM) were then passed over the chip to measure binding. 
Regeneration was performed with 10 mM Glycine pH 2.0. Nonspecific binding was 
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determined using a flow cell on a chip without antigen. Binding kinetics were analyzed 
by using BIAcore 3000 software. 
3.2.7 In Vitro Cytotoxicity  
The ability for bscEGFRvIIIxCD3 or nonspecific tandem scFv to redirect 
cytotoxicity from previously unstimulated human PBMCs was analyzed by standard 
chromium release assay in round-bottom 96-well plates.  Briefly, target cells were 
labeled with 51Cr and incubated with bscEGFRvIIIxCD3 at 10 µg/mL.  PBMCs were 
then added at effector-to-target (E:T) ratio (20:1) to each well, after which the plates were 
centrifuged and incubated at 37 °C for 18 hours.  The supernatant was then removed 
and measured by gamma counter.   
3.3 Results 
3.3.1 Design, Expression and Purification of bscEGFRvIIIxCD3  
To construct an EGFRvIII-specific bscAb, we selected an affinity-matured anti-
human EGFRvIII-specific scFv, MR1-1 (Kuan et al., 2000), and translated it in tandem 
with a scFv isolated from the anti-human CD3 monoclonal antibody (mAb), OKT3.  
Briefly, two scFvs directed against EGFRvIII and CD3, respectively, were joined by a 
flexible five-amino acid (Gly4Ser) linker using overlap extension polymerase chain 
reaction in the following variable domain orientation:  VH-VL-VH-VL.   
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Figure 8:  Schematic of variable region sequence of bscEGFRvIIIxCD3. 
Schema of bscEGFRvIIIxCD3 design. Linkers L1 and L3 were constructed between the 
VH and VL domains of their respective scFvs and consist of (Gly4Ser)3, while L2 was 
constructed as a single Gly4Ser linker between scFvs. 
 
The resultant tandem single-chain bscAb, bscEGFRvIIIxCD3, was expressed in 
transformed E. coli, isolated from insoluble inclusion bodies and verified for identity by 
Western blot.  Refolded bscAb was purified by metal affinity chromatography with a 
distinct peak observed in the elution profile between 50 and 100 mM imidazole.  
Fractions were collected and tested for purity by SDS-PAGE, indicating a single band of 
refolded bscAb with a predicted molecular weight of approximately 52 kDa.  In a typical 
preparation cycle, 100 mg of inclusion bodies from 1 L of culture yielded 1-2 mg of 
purified bscEGFRvIIIxCD3.  
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Figure 9:  Purification of solubilized inclusion bodies by metal affinity 
chromatography. 
(Left) BscEGFRvIIIxCD3 was expressed as insoluble inclusion bodies and verified for 
identity by SDS-PAGE and Western Blot with anti-His-tag antibody.  (Center) Protein 
was eluted from an immobilized metal affinity chromatography column by stepwise 
imidazole gradient.  Representative gel from corresponding fractions is shown below.  
(Right) SDS-PAGE of eluted fraction indicated by arrow in center panel. Molecular 
weight markers (kDa) are shown on the right. 
 
For the sake of simplicity, we will save discussion regarding further 
characterization of the EGFRvIII BiTE until the next chapter.  The immediate sections 
that follow will introduce a new method that we have developed to produce negative 
control, or inert, tandem scFvs.  Importantly, these control constructs represent a 
necessary aspect of our downstream evaluation of the EGFRvIII BiTE and thus warrant 
detailed discussion here.   
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3.3.2 Rational Design of Control Reagents for the Evaluation of 
Bispecific Tandem ScFvs 
Properly controlled experiments are essential to the execution of science.  As 
such, a project that seeks to develop a novel biological therapy must also consider the 
development of parallel control reagents; that is to say, molecules that are carefully 
designed to be as similar to the active agent as possible, but altered slightly so as to 
reveal the features of the molecule that are necessary to mediate a given activity of 
interest—in this case, antitumor efficacy.  One way that this concept applies to the field 
of bispecifics is the production of tandem scFv constructs that maintain specificity for 
the CD3 T-cell activating complex, yet no longer possess reactivity to surface antigens 
present on tumor cells.  The incorporation of such a molecule as a negative control 
would allow us to define whether observed antitumor functions were strictly dependent 
on dual binding specificities, or whether other potential mechanisms were at play that 
would otherwise suffice for eliciting BiTE-related immune activation.   
In order to create a tandem scFv that could serve as a negative control in our 
experiments, we first identified a monoclonal antibody clone, MOPC-21 (mouse IgG1, 
κ), with no known binding specificity.  MOPC-21 was chosen, particularly because it has 
been screened for reactivity on a variety of resting, activated, live, and fixed rodent and 
human tissues, and has been shown to be virtually inert in these settings.  In our hands, 
we were able to verify that indeed, while an anti-EGFRvIII antibody clone, L8A4, bound 
to glioma cells transfected to express EGFRvIII (U87MG.∆EGFR), MOPC-21 did not have 
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appreciable binding on either the parental wild-type expressing U87MG or 
U87MG.∆EGFR by flow cytometric analysis.  
 
Figure 10:  Monoclonal antibody MOPC-21 does not bind to EGFRvIII+ tumor. 
 
Next, we sought to develop a scFv from the MOPC-21 antibody, and translate it 
in tandem with the OKT3 scFv that we had been previously incorporated into the 
EGFRvIII BiTE.  The intention was to create a tandem scFv that retained the ability to 
bind CD3 while losing all potential reactivity with target tumor cells. 
Unfortunately, we discovered that the new tandem scFv based on the MOPC-21 
monoclonal antibody no longer refolded in a conformation that allowed binding to CD3 
via the OKT3 scFv domain.  This effect was most likely due to nuances associated with 
refolding conditions that we had previously optimized for the EGFRvIII BiTE.  Based on 
the few published attempts at refolding tandem scFvs in this fashion—which were 
largely unsuccessful (Kipriyanov et al., 2003, Mallender and Voss, 1994, Gruber et al., 
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1994)—we theorized that to some degree, each individual protein likely exhibits 
idiosyncrasies that would prevent achieving identical anti-CD3 bioactivity (e.g., 
conformation, affinity) through bacterial expression of insoluble inclusion bodies, given 
the highly variable processes by which non-native proteins refold in solution.  Thus, we 
formulated an alternative method to ablate target cell binding activity while preserving 
the general refolding properties of bispecific tandem scFv molecules, through limited 
mutagenesis directed at short portions of complementarity determining regions (CDR).  
3.3.2.1 CDR Site-Directed Mutagenesis as a Method to Produce Negative Control 
Bispecific Antibody Reagents 
Since altering one of the two scFvs present in the bispecific molecule was 
sufficient to abolish native refolding properties, we sought to disrupt binding of the 
EGFRvIII BiTE to the EGFRvIII tumor antigen through mutations focused on more 
restricted portions of MR1-1.  In order to guide our strategy, we carefully examined 
previously published protein crystal structures (PDB:  18I8) (Landry et al., 2001) of a 
closely related scFv, MR1, in complex with the PEPvIII antigen using UCSF Chimera 
software.  Our analysis revealed that three CDR domains appeared to be responsible for 
primary interactions with PEPvIII residues:  CDR 2 and 3 of the variable heavy chain 
(H2 and H3 of VH) and CDR3 of the variable light chain (L3 of VL).     
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Figure 11:  MR1 in complex with PEPvIII (PDB:  18I8). 
Side (left panel) and bottom (right panel) views of MR1 in complex with peptide 
antigen reveals apparent interaction between side chains of the antigen substrate and 
primarily CDRs H2, H3 and L3. 
 
In addition, UCSF Chimera also provided a quantifiable measure of interactions 
between side chains of the antigen and the scFv of interest, primarily through 
approximated measures of intermolecular hydrogen bonds.  These data confirm that, 
among the hydrogen bonds estimated to most influence binding, CDRs corresponding 
to H2, H3 and L3 were most widely implicated.   
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Table 6:  Hydrogen bonds between EGFRvIII antigen and MR1 CDRs approximated 
by UCSF Chimera. 
Peptide CDR Hbond partner Å 
502.C Lys N H3 403.B Thr O 3.120 
503.C Gly N L3 92.A Phe O 2.842 
505.C Tyr OH H3 405.B Tyr N 3.056 
505.C Tyr OH L3 91.A Ser O 2.721 
506.C Val N H2 359.B Tyr OH 2.795 
507.C Val O H2 353.B Thr N 2.863 
508.C Thr O
γ1
 H3 402.B Ser O 2.757 
509.C Asp O
δ2
 H2 352.B Ser O
γ
 2.832 
 
Based on the above analyses, we sought to perform mutagenesis on the CDRs 
most likely involved with binding to key residues of the EGFRvIII antigen as 
determined by UCSF Chimera software.  We hypothesized that replacing MR1-1 CDR 
residues with analogous residues from the MOPC-21 clone scFv, p588, would allow us 
to abolish EGFRvIII specificity, without disrupting the natural architecture of what 
could be a biochemically stable CDR domain.  Prior to performing the mutagenesis, we 
aligned the CDRs of the variable heavy and variable light chains of MR1-1 and p588, 
using conserved residues present in the backbone of each scFv to anchor our analysis.   
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Figure 12:  Alignment of CDR domains between MR1-1 and p588 variable chains. 
Disparities between MR1-1 and p588 CDR residues in H2, H3 and L3 are highlighted in 
red text.  Underlined residues indicate those to be replaced with corresponding residues 
present in the p588 scFv.  Targeted mutagenesis as indicated for all three regions would 
result in an overall sequence homology between the two molecules of greater than 94% 
(bottom panel). 
 
We next sought to express and purify the mutagenized tandem scFv—which was 
94.4% homologous by cDNA sequence with the EGFRvIII BiTE—according to the 
methods previously optimized for the EGFRvIII BiTE.  In line with our predictions, the 
mutagenized bispecific antibody containing the scFv, H3.H2.L3, behaved similarly to the 
EGFRvIII BiTE under the same conditions throughout the processes of expression, 
refolding and purification.  Importantly, we were able to purify H3.H2.L3 to a single 
band of an expected molecular weight, approximately 52 kDa.   
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Figure 13:  SDS-PAGE of H3.H2.L3 demonstrates highly pure protein product. 
Molecular weight ladder is listed on the left demonstrates purification of a protein 
approximately 52 kDa. 
 
When compared with EGFRvIII BiTE, the mutant H3.H2.L3 did not bind at 
detectable levels when tested against EGFRvIII-expressing tumors by flow cytometric 
analysis.  However, H3.H2.L3 did continue to bind the CD3 surface antigen on both 
CD4+ and CD8+ T cells, which were stained as a fraction of human PBMC.  These data 
were the first evidence that demonstrated our successful production of an adequate 
control bispecific tandem scFv with high sequence homology to the original EGFRvIII.   
In addition, we employed surface plasmon resonance to quantify whether there 
were any significant differences with regard to CD3 bioactivity between the EGFRvIII 
BiTE and the tandem scFv mutant that may have been beneath the limit of detection of 
flow cytometric analysis.  In our analysis, while EGFRvIII BiTE bound as expected to 
both EGFRvIII extracellular domain and to CD3ε, the H3.H2.L3 mutant demonstrated 
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no detectable binding (NDB) to EGFRvIII antigen, while maintaining virtually 
indistinguishable kinetics from the EGFRvIII BiTE with regard to CD3ε.   
 
Figure 14:  The H3.H2.L3 mutation ablates EGFRvIII binding while maintaining 
specificity for CD3 by flow cytometry. 
H3.H2.L3 no longer binds to tumors expressing EGFRvIII (U87MG.∆EGFR) (Left Panel), 
but continues to bind to T cells that coexpress surface CD4 and CD8 (Middle and Right 
Panels, respectively). 
 
Table 7:  The H3.H2.L3 mutation demonstrates no detectable binding to EGFRvIII by 
surface plasmon resonance but continues to bind CD3 at expected levels. 
 Kd (M) kon (M-1s-1) koff (s-1) Kd (M) kon (M-1s-1) koff (s-1) 
EGFRvIII 1.5 x 10-9 4.6 x 104 8.1 x 10-4 NDB NDB NDB 
CD3 6.5 x 10-9 6.61 x 104 4.29 x 10-4 5.6 x 10-9 3.2 x 104 1.8 x 104 
 EGFRvIII BiTE H3.H2.L3 
 
Lastly, based on the well-characterized capacity of antibodies to recognize a vast 
array of antigenic substrates through relatively minor permutations of V(D)J 
recombination, we hypothesized that even single CDR mutations would be sufficient to 
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significantly abrogate EGFRvIII binding and thus antitumor efficacy of the EGFRvIII 
BiTE.  Towards this end, we created three additional tandem scFvs, one of each with 
individual H3, H2 or L3 mutant CDRs, again corresponding to residues from the 
nonspecific scFv, p588.  As expected, we were able to refold and purify all gene products 
following site-directed mutagenesis, without having to otherwise alter our 
methodology.  The highest sequence homology achieved was 98.8%, which reflected a 
change of six amino acids in H3, a relatively small portion of the entire tandem scFv.   
 
Figure 15:  SDS-PAGE demonstrates that single CDR mutant tandem scFvs can be 
purified with high fidelity to create negative control tandem scFvs. 
H3, H2 and L3 single CDR mutants are purified by metal affinity chromatography and 
are represented here as a band approximately 52 kDa.  Molecular weight markers are 
shown on the left.   
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Table 8:  Sequence homology among all mutant tandem scFv included in the study. 
 
Importantly, we not only sought to abrogate the capacity of mutant tandem 
scFvs to bind EGFRvIII by measures of flow cytometry and surface plasmon resonance, 
but also performed functional tests to evaluate whether EGFRvIII-targeted BiTEs would 
mediate immune responses against tumors expressing EGFRvIII, and whether this 
activity would be dependent on dual binding specificity in vivo (as demonstrated by 
absence of cytotoxicity in the presence of the negative control molecule).  In a standard 
chromium release assay, EGFRvIII BiTE was shown to mediate specific lysis against 
EGFRvIII-expressing glioma in vitro.  Here, the mutated tandem scFvs—which all 
retained the ability to bind CD3—were unable to redirect a similar response against 
EGFRvIII-expressing cells.   
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Figure 16:  Single CDR mutagenized tandem scFvs can serve as highly homologous, 
negative control molecules for the preclinical evaluation of BiTEs.   
Standard 51Cr-release demonstrates specific lysis of U87MG.ΔEGFR by unstimulated 
human PBMCs and bscEGFRvIIIxCD3 (+), as well as four other mutagenized constructs 
meant to serve as negative controls (E:T ratio 20:1; incubation time 18 hours; [tandem 
scFv] 10 μg/mL 
 
This finding and other aspects of characterization regarding BiTE mediated 
antitumor activity will be the central premise of the chapter that follows.   
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4 Systemic Administration of a Bispecific Antibody 
Targeting EGFRvIII Successfully Treats Intracerebral 
Glioma 
4.1 Introduction 
Bispecific antibodies (bscAbs), particularly those of the bispecific T-cell engager 
(BiTE) subclass, have been shown to effectively redirect T cells against cancer.  
To date, various mouse models and clinical trials have demonstrated the great 
potential of antibody-redirected T-cell therapies, either through chimeric antigen 
receptors (CARs) or more recently via BiTEs against tumor-associated antigens including 
ErbB-2, CEA, and CD19 (Baeuerle and Reinhardt, 2009, Brentjens et al., 2010, Morgan et 
al., 2010, Klinger et al., 2012).  However, because these targets are not strictly limited to 
tumor tissue, such approaches have led to unwanted toxicity and destruction of even 
normal, healthy cells (Bargou et al., 2008, Heslop, 2010).  Moreover, like other large 
molecules, bscAbs may be restricted from entry into the “immunologically-privileged” 
CNS. 
In previous chapters, we have discussed in detail the several advantages of 
therapeutically targeting the EGFRvIII tumor-specific antigen.  EGFRvIII is a 
constitutively-activated tyrosine kinase not found in normal tissues, but frequently 
expressed in GBM and many other neoplasms.  Because it is solely localized to tumor 
tissue, EGFRvIII represents an ideal target for immunotherapy. 
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Here, we describe the preclinical evaluation of the EGFRvIII-targeted BiTE, 
bscEGFRvIIIxCD3, the design and manufacture of which was detailed in the preceding 
chapter.  Importantly, our results show that bscEGFRvIIIxCD3 activates T cells to 
mediate potent and antigen-specific lysis of EGFRvIII-expressing glioma in vitro (p<.001) 
at exceedingly low concentrations (10 ng/mL) and effector-to-target ratios (2.5:1).  
Intravenous treatment with bscEGFRvIIIxCD3 led to extended survival in mice with 
well-established intracerebral tumors (p<.05) and achieved durable complete cures at 
rates up to 75%.  Antitumor efficacy was significantly abrogated upon blockade of 
EGFRvIII-binding, demonstrating the need for target-antigen specificity both in vitro and 
in vivo.   
These results demonstrate for the first time that BiTEs can be used to elicit 
functional antitumor immunity in the CNS.  Moreover, peptide blockade of BiTE-
mediated activity is shown to be a novel strategy that may greatly enhance the safety 
profile for antibody-redirected T-cell therapies.  Finally, bscEGFRvIIIxCD3 represents a 
unique advance in BiTE technology given its exquisite tumor-specificity, which enables 
precise elimination of cancer without the risk of autoimmune toxicity.  
4.2 Materials and Methods 
4.2.1 Mice and Tumor Cell Lines 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, also known as NOD scid gamma (NSG) mice, 
were purchased from The Jackson Laboratory and were bred under pathogen-free 
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conditions at Duke University.  All animal experiments were performed according to 
protocols approved by the Duke University Institutional Animal Care and Use 
Committee.  The human glioma cell lines U87MG and D54, as well as their respective 
sublines, U87MG.ΔEGFR and D54-EGFRvIII have been previously described 
(Nishikawa et al., 1994, Lal et al., 2002). 
4.2.2 Flow Cytometric Analysis 
Lymphocytes were incubated for 15 minutes at room temperature with 
combinations of titrated antibodies to CD4 (RPA-T4), CD8 (RPA-T8), CD25 (M-A251) 
and CD69 (L78).  Cells were washed and analyzed on a BD Biosciences FACSCalibur 
flow cytometer.  Data analysis was performed using BD FloJo software.  In certain 
experiments, bscEGFRvIIIxCD3 was added to lymphocytes or tumor cells at a 
concentration of 10 μg/mL and allowed to incubate for 15 minutes at room temperature.  
Cells were washed and incubated with Penta-His Alexa Fluor 488 Conjugate (Qiagen) 
and analyzed as above. 
4.2.3 Proliferation Assay 
In experiments assessing proliferation, 1 μCi 3H-thymidine was added to each 
well of a 96-well plate.  Cells were cultured for an additional 24 hours and collected by a 
cell harvester.  Counts were performed using a Wallac 1450 Microbeta Trilux Liquid 
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Scintillation/Luminescence Counter (Perkin-Elmer) and data were recorded as means of 
triplicate wells.  
4.2.4 T-cell Activation and Cytometric Bead Array 
Freshly thawed PBMCs were placed in 96-well plates with bscEGFRvIIIxCD3 (10 
μg/mL) and target cells at an E:T ratio of 20:1 in a total volume of 200 μL.  Supernatant 
was removed after incubation for 48 hours at 37 °C and analyzed by manufacturer’s 
instructions.  Cells were also harvested and analyzed for activation markers as above.  
4.2.5 In vitro Cytotoxicity 
The ability for bscEGFRvIIIxCD3 to redirect cytotoxicity from previously 
unstimulated human PBMCs was analyzed by standard chromium release assay in 
round-bottom 96-well plates.  Briefly, target cells were labeled with 51Cr and incubated 
with bscEGFRvIIIxCD3 at varying concentrations.  PBMCs were then added at various 
effector-to-target (E:T) ratios (ranging from 1:1 to 20:1) to each well, after which the 
plates were centrifuged and incubated at 37 °C for 18 hours.  The supernatant was then 
removed and measured by gamma counter.  Where noted, peptide blockade was 
performed with the addition of PEPvIII to wells at a 1:1 ratio by mass with 
bscEGFRvIIIxCD3.  In certain experiments, target cells were labeled using PKH26 red 
fluorescent cell linker kit (Sigma) and effector cells were labeled using intracellular 
carboxyfluorescein diacetate succinimidyl ester (CFSE) according to manufacturer 
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instructions. Cells were then visualized across multiple time points using a Nikon 
Eclipse TE2000-E fluorescent microscope. 
4.2.6 Tumor Implantation 
U87MG and U87MG.ΔEGFR were grown in improved MEM zinc option media 
with 10% FBS.  Tumor cells were collected in logarithmic growth phase, washed twice 
with PBS, and mixed with an equal volume of 10% methyl cellulose prior to loading into 
a 250 μL syringe with an attached 25 gauge needle.  The needle was positioned using a 
stereotactic frame at 2 mm to the right of the bregma and 4mm below the surface of the 
skull at the coronal suture.  The tumorigenic dose was 1 x 105 cells in a total volume of 5 
μL. For certain experiments, freshly thawed human PBMCs were resuspended with 
tumor cells prior to inoculation at a ratio of 1:1.  Treatment with bscEGFRvIIIxCD3 was 
infused in a total volume of 250 μL by tail vein injection on the indicated days following 
tumor implantation.  Where noted, peptide blockade was performed with the co-
infusion of soluble PEPvIII by tail vein at a 1:1 ratio with bscEGFRvIIIxCD3. 
4.2.7 Statistical Analysis 
Unless otherwise stated, groups were compared using a two-sample two-tailed t-
test to determine statistical significance. Survival curves were estimated for each group 
using the product-limit estimation of Kaplan and Meier.  Primary comparative analyses 
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of the curves for each group were performed using the generalized Wilcoxon test. 
Statistical significance was determined at a value of P < 0.05. 
4.3 Results 
4.3.1 BscEGFRIIIxCD3 Redirects T cells Against Tumor Cells in Vitro 
First, we sought to test bscEGFRvIIIxCD3 for its ability to activate T cells in vitro. 
When incubated with bscEGFRvIIIxCD3 and target cells, CD4+ and CD8+ T cells 
upregulated surface expression levels of activation markers CD69 and CD25.  
Importantly, this required interaction with the EGFRvIII antigen, since elevated CD69 
and CD25 expression was detected only in the presence of EGFRvIII-expressing human 
glioma cells compared to wild-type parental controls. 
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Figure 17:  Expression of activation markers on T cells redirected by 
bscEGFRvIIIxCD3. 
T cells incubated with bscEGFRvIIIxCD3 and either U87MG.ΔEGFR (black line) or 
U87MG (grey line) were stained and analyzed for surface expression of activation 
markers CD69 and CD25. 
 
 The ability of bscEGFRvIIIxCD3 to induce antigen-specific proliferation of T 
cells was also measured by 3H-thymidine incorporation in vitro.  In these experiments, 
recombinant EGFRvIII extracellular domain (ECD) was used as a source of cognate 
antigen in order to remove the variability in 3H-thymidine incorporation that would 
otherwise occur due to proliferation of target glioma cells.  When soluble 
bscEGFRvIIIxCD3 was incubated in the presence or absence of solid-phase bovine 
serum albumin (BSA), proliferative effects were not detected above baseline levels. 
However, soluble bscEGFRvIIIxCD3 in the presence of solid-phase EGFRvIII ECD led to 
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significant proliferation that was indistinguishable from stimulation with solid-phase 
bscEGFRvIIIxCD3 alone.  This verified that—as has been well-characterized for BiTEs 
against other antigens—interaction between soluble bscEGFRvIIIxCD3 and the 
EGFRvIII target is necessary in order to potentiate immunological capping and synapse 
formation, and that antigen-specificity represents a crucial factor mediating this activity 
(Offner et al., 2006). 
 
Figure 18:  BiTE-redirected T cells proliferate in the presence of EGFRvIII. 
Proliferation of T cells in response to bscEGFRvIIIxCD3 and solid phase EGFRvIII ECD 
was measured by 3H-thymidine incorporation.  *** P < 0.001. 
 
Effective antitumor immune responses are known to require the secretion of 
inflammatory cytokines, particularly those associated with TH1 polarization. To test 
whether activation of T cells by bscEGFRvIIIxCD3 leads to favorable cytokine 
production, cytometric bead array was used to analyze the supernatants of cultures in 
which lymphocytes were incubated with bscEGFRvIIIxCD3 and target cells either 
 91 
expressing or not expressing the EGFRvIII tumor-specific antigen. In the presence of 
negative control target cells, analyses of culture supernatants revealed minimal secretion 
of IL-2, IFN-γ and TNF. However, when incubated with EGFRvIII-expressing glioma, 
bscEGFRvIIIxCD3 elicited significantly greater T-cell function, which, when represented 
as proportions in a multiplex cytokine panel, demonstrated considerable polarization 
toward a TH1-associated immune response.  
 
Figure 19:  CBA anlaysis of supernatants from BiTE-redirected T cells in vitro. 
Supernatants from wells containing unstimulated human PBMCs with 
bscEGFRvIIIxCD3 and either U87MG.ΔEGFR or U87MG were subjected to CBA analysis 
for inflammatory cytokines, demonstrating elevated secretion of IL-2, IFN-γ, and TNF in 
the presence of U87MG.ΔEGFR.  *** P < 0.001. 
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Figure 20:  EGFRvIII BiTEs elicit Th1 polarized cytokine secretion. 
  
Next, we sought to test bscEGFRvIIIxCD3 for its ability to functionally elicit 
antigen-specific cytotoxic responses in vitro.  In a standard 51Cr release assay using 
freshly-thawed human PBMCs as effector cells, we determined that bscEGFRvIIIxCD3-
mediated redirection of T cells is indeed highly cytotoxic against multiple previously 
characterized human EGFRvIII-expressing tumor cells (Lal et al., 2002).   
 
Figure 21:  BiTEs redirect  T cells to kill EGFRvIII tumor in vitro. 
Standard 51Cr-release demonstrates specific lysis of U87MG.ΔEGFR over U87MG (left 
panel) and D54-EGFRvIII over D54 (right panel) by unstimulated human PBMCs and 
bscEGFRvIIIxCD3 (E:T ratio 20:1; incubation time 18 hours; [bscEGFRvIIIxCD3] 10 
μg/mL).  *** P < 0.001, ** P < 0.01. 
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Importantly, cytotoxicity was strictly dependent on the ability for 
bscEGFRvIIIxCD3 to recognize and bind to the EGFRvIII antigen on target cells, since 
incubation of bscEGFRvIIIxCD3 with matched EGFRvIII-negative tumors in the 
presence of effector cells did not induce observable target-cell lysis.  Furthermore, 
demonstrating the need for dual specificity within the actual therapeutic molecule, 
target-cell lysis was not observed upon incubation with a nonspecific bscAb control 
bscAbxCD3—which was designed from antigen-binding portions isolated from isotype 
clone MOPC-21 and OKT3, as detailed in the previous chapter—but was maintained 
against EGFRvIII-expressing cells upon incubation with the active molecule, 
bscEGFRvIIIxCD3.   
 
Figure 22:  Cytotoxic effects mediated by EGFRvIII BiTEs depend on dual specificity. 
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Specific lysis of the U87MG.ΔEGFR cell line is not observed in the presence of negative 
control bscAbxCD3 compared to incubation with bscEGFRvIIIxCD3 (E:T ratio 20:1; 
incubation time 18 hours; [bscEGFRvIIIxCD3] 10 μg/mL). 
 
In addition to being highly specific, the bioactivity of bscEGFRvIIIxCD3 was also 
potent against EGFRvIII-expressing tumor at greatly reduced concentrations, with dose-
dependence observed at E:T ratios as low as  2.5:1. 
 
Figure 23:  The effects of bscEGFRvIIIxCD3 are potent and dose dependent in vitro. 
Specific lysis of the U87MG.ΔEGFR cell line varies proportionally with 
bscEGFRvIIIxCD3 concentration and dose response is maintained over varied E:T ratios.  
* P < 0.05. 
 
When visualized by light microscopy, bscEGFRvIIIxCD3 did not appear to affect 
the behavior of lymphocytes against EGFRvIII-negative glioma cells in vitro. However, 
in the presence of EGFRvIII expression on the surface of matched glioma, lymphocytes 
visibly localized to the surface of tumor cells upon addition of bscEGFRvIIIxCD3, 
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implying that the cytotoxic effects observed in vitro may occur via contact-mediated 
mechanisms.   
 
Figure 24:  Antigen-specific co-localization of lymphocytes and tumor cells in the 
presence of bscEGFRvIIIxCD3 in vitro. 
Light microscopy of T cells incubated with U87MG in the presence of bscEGFRvIIIxCD3 
does not demonstrate appreciable localization to tumor (top panel) compared to wells in 
which target cells expressing EGFRvIII, U87MGΔEGFR, were included (bottom panel). 
Importantly, under conditions wherein PKH26-labeled EGFRvIII-positive (red) 
and matched EGFRvIII-negative (bright field) glioma cells were cultured together in 
close proximity, bscEGFRvIIIxCD3-redirected CFSE-labeled T cells (yellow) were seen to 
localize only to EGFRvIII-expressing tumor.  These results lend further credence to the 
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ability of the BiTE therapeutic platform to selectively distinguish between even closely-
associated, adjacent cells based on target antigen expression in vitro. 
 
Figure 25:  Co-culture of fluorescently labeled lymphocytes and target tumor cell lines 
+/- EGFRvIII expression in vitro. 
Experiments were also performed where U87MG (bright field), labeled U87MG.ΔEGFR 
(red) and T cells (yellow) were incubated with bscEGFRvIIIxCD3, which demonstrated 
selective localization of T cells to EGFRvIII-expressing tumor cells in vitro.   
4.3.2 The Antitumor Response Produced by BscEGFRvIIIxCD3 is 
Specific to EGFRvIII-Expressing Tumors in Vivo 
To investigate the in vivo activity of bscEGFRvIIIxCD3, we established orthotopic 
xenograft models using the human malignant glioma cell lines U87MG and 
U87MG.ΔEGFR.  A number of studies have recently demonstrated that GBMs are 
infiltrated by immune cells (Yang et al., 2010, Lohr et al., 2011); thus, in order to model 
this scenario preclinically, NSG mice were inoculated intracranially with a mixture of 
tumor cells and unstimulated human PBMCs.  Following implantation, 
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bscEGFRvIIIxCD3 was administered via daily tail vein injections.  Under these 
conditions, we observed that mice implanted with tumors expressing only the wild-type 
EGFR did not exhibit a significant survival benefit.  Similarly, in mice implanted with 
intracerebral tumors expressing EGFRvIII, treatment with the nonspecific control 
bscAbxCD3 did not prolong survival over mice receiving vehicle control.   
 
Figure 26:  EGFRvIII BiTE does not treat EGFRvIII-negative tumors in vivo. 
NSG mice were implanted intracerebrally with 1x105 tumor cells and unstimulated 
human PBMCs at a ratio of 1:1.  Mice implanted with U87MG were treated with 
bscEGFRvIIIxCD3 by daily intravenous infusion (arrows).  
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Figure 27:  In vivo efficacy of the EGFRvIII BiTE is specific. 
NSG mice (n=8) were implanted intracerebrally with 1x105 tumor cells and unstimulated 
human PBMCs at a ratio of 1:1.  Mice implanted with U87MG.ΔEGFR were treated with 
bscEGFRvIIIxCD3 or control bscAbxCD3 by daily intravenous infusion (arrows).  
 
However, infusion with bscEGFRvIIIxCD3 in this setting achieved durable, 
complete cures in 6/8 mice without apparent toxicity; this effect was also potent and 
dose-dependent, yielding prolonged survival at doses as low as 1 μg/mouse/day, with 
comparable results observed in repeated experiments . 
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Figure 28:  The antitumor activity of bscEGFRvIIIxCD3 against EGFRvIII-expressing 
tumor is potent and dose-dependent in vivo. 
Mice implanted with U87MG.ΔEGFR were treated with bscEGFRvIIIxCD3 by daily 
intravenous infusion (arrows).  To assess dose response, bscEGFRvIIIxCD3 was 
administered to mice at indicated doses. 
 
4.3.3 Antitumor Efficacy of BscEGFRvIIIxCD3 is Abrogated by 
EGFRvIII Blockade. 
Despite early evidence of success in the clinic, recent antibody-redirected T-cell 
platforms have been shown to induce lethal “on-target” toxicity when their cognate 
antigen is not only present in tumors but also expressed in normal, healthy tissues (e.g., 
ErbB-2, CEA and CD19) (Baeuerle and Reinhardt, 2009, Brentjens et al., 2010, Morgan et 
al., 2010, Klinger et al., 2012).  To address this issue in our model—and to provide 
additional controls demonstrating the specificity of our approach—we sought to 
determine whether competitive inhibition of EGFRvIII-binding could directly abrogate 
biological activity of bscEGFRvIIIxCD3 both in vitro and in vivo.  The rationale for this 
hypothesis was based on our data showing that bscEGFRvIIIxCD3 is not effective in the 
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absence of EGFRvIII-expression on tumors, and that similarly, a control bscAbxCD3 is 
not effective in the presence of EGFRvIII-expressing tumors; these data demonstrated 
that the anti-CD3 moiety alone does not mediate direct antitumor effects.  Importantly, 
our inclusion of selective EGFRvIII-blockade here also provides an additional control 
that further demonstrates the exquisite specificity of the BiTE platform. 
To perform specific EGFRvIII blockade, we employed a previously-published 
soluble peptide (PEPvIII) corresponding to the extracellular epitope for EGFRvIII-
specific antibodies (Heimberger et al., 2003).  Importantly, this peptide is currently in 
clinical trials as an EGFRvIII-targeted vaccine, and thus possesses great translational 
potential in addition to providing biologic principle.  Using this approach, our data 
demonstrate that EGFRvIII blockade by PEPvIII successfully disrupts binding to 
EGFRvIII-expressing tumor targets in vitro; importantly, PEPvIII inhibition was specific 
since peptide-blocked bscEGFRvIIIxCD3 retained the ability to bind the CD3 complex 
on both CD4+ and CD8+ T cells.  
 
Figure 29:  PEPvIII peptide blockade abrogates binding to tumor cells expressing 
EGFRvIII. 
 101 
EGFRvIII blockade does not impact the ability for bscEGFRvIIIxCD3 to bind CD4+ or 
CD8+ T cells, but significantly abrogates binding to EGFRvIII-expressing glioma in vitro. 
 
Despite continued anti-CD3 binding, addition of the cognate PEPvIII peptide 
was sufficient to completely abolish bscEGFRvIIIxCD3-mediated antitumor effects 
against EGFRvIII-expressing glioma in vitro.  Moreover, EGFRvIII blockade significantly 
reduced efficacy of bscEGFRvIIIxCD3 in vivo against EGFRvIII-expressing tumor in the 
brain.  
 
Figure 30:  Blockade of BiTE-mediated antitumor activity in vitro with 
EGFRvIII peptide blockade. 
Standard 51Cr-release demonstrates specific lysis of U87MG.ΔEGFR in the presence of 
bscEGFRvIIIxCD3 and effector cells (E:T ratio 20:1; incubation time 18 hours; 
[bscEGFRvIIIxCD3] 10 μg/mL) which is completely inhibited in the presence of soluble 
PEPvIII cognate peptide (blockade ratio 1:1). *** P < 0.001. 
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Figure 31:  Antitumor efficacy of EGFRvIII BiTE is abrogated upon PEPvIII blockade 
in vivo. 
NSG mice (n=8) were implanted i.c. with 1x105 U87MG.ΔEGFR and unstimulated human 
PBMCs at a ratio of 1:1. Daily intravenous infusions with bscEGFRvIIIxCD3, co-infusion 
with PEPVIII blockade, or PBS vehicle control began 3 hours after implantation and 
continued for 5 days (arrows). 
 
Together, these results validate the precise target-specificity of the 
bscEGFRvIIIxCD3 construct and definitively establish the need for dual-binding given 
that, upon EGFRvIII blockade, effector-arm interactions with CD3 alone were not 
sufficient to achieve antitumor activity.  In addition, our finding that a soluble cognate 
peptide can be used to selectively inhibit therapeutic effects of bscEGFRvIIIxCD3 may 
offer a novel approach to enhancing the safety profile of other bscAbs that target 
antigens expressed in normal, healthy tissues. 
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4.3.4 BscEGFRvIIIxCD3 Recruits Circulating Immune Cells to Treat 
Intracerebral Tumors 
Because bscEGFRvIIIxCD3 proved to potently eliminate intracerebral glioma in 
the presence of even small numbers effector cells, we investigated whether treatment 
with an EGFRvIII-specific bscAb would lead to the recruitment and accumulation of 
circulating peripheral lymphocytes to EGFRvIII-expressing glioma cells in the brain.  To 
explore this possibility, tumor cells alone were implanted intracerebrally in mice and 
allowed to establish for 10 days.  Animals were then immune-reconstituted by i.p. 
infusion with human PBMCs and treated with bscEGFRvIIIxCD3 by tail vein in the 
same manner as previously described.  Tumors examined from mice receiving vehicle 
(PBS) did not exhibit visible immune infiltrate upon histological analysis and instead 
showed invasive tumor tissue extending along peritumoral blood vessels .  However, in 
mice receiving bscEGFRvIIIxCD3, peripherally-infused PBMCs were observed to leave 
peritumoral vessels and traffic toward EGFRvIII-expressing tumor within the brain. 
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Figure 32:  Perivascular lymphocytic cuffing is associated with intracerebral vessels in 
mice treated with EGFRvIII BiTE. 
NSG mice (n=5) were implanted intracerebrally with 1x105 U87MG.ΔEGFR.  On Day 10 
following tumor implantation, animals were immune-reconstituted peripherally with 
2x107 unstimulated human PBMCs by intraperitoneal injection.  Daily intravenous 
infusions with bscEGFRvIIIxCD3 (10 μg/mouse/day) or PBS began on day 10 and were 
continued for 5 days after which mice were sacrificed and processed for histological 
sectioning. (Left) Representative section of intracerebral tumor and local invasion 
surrounding an adjacent vessel in an animal receiving PBS.  (Right) By contrast, in mice 
treated with bscEGFRvIIIxCD3, PBMCs are seen to exit peritumoral vessels toward 
tumor tissue (box). 
 
Moreover, areas of residual EGFRvIII-expressing tumor in treated mice revealed 
heavy mononuclear infiltrate and regions of necrotic tumor.   
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Figure 33:  Representative section of residual tumor in treated mice. 
Tumor tissue in mice treated with bscEGFRvIIIxCD3 and receiving intraperitoneal 
PBMCs shows diffuse tumor-associated mononuclear infiltrate and areas of necrosis. 
 
Due to the dramatic impact of bscEGFRvIIIxCD3 on intracerebral localization of 
cellular immunity, we reasoned that this effect might also be therapeutic against late-
stage, established tumors.  To test this, animals were peripherally immune-reconstituted 
and treated with bscEGFRvIIIxCD3 just 5 days before the median survival of mice under 
control conditions.  Our data demonstrate that even a moderate dose (10 μg x 5d) of 
bscEGFRvIIIxCD3 was sufficient to recruit and activate lymphocytes to significantly 
extend survival in mice with established, late-stage EGFRvIII-expressing tumors in the 
brain.  This result was achieved using a cumulative dose of bscEGFRvIIIxCD3 
approximately 10-fold below the pharmacological equivalent of current, clinically-
approved antibody therapies. 
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Figure 34:  Delayed treatment of established intracerebral glioma with BiTE. 
For delayed treatment, animals were immune-reconstituted peripherally with 2x107 
unstimulated human PBMCs by intraperitoneal injection on day 10, followed by 
infusion with EGFRvIII BiTE. 
 
Overall, these data demonstrate that systemic administration of 
bscEGFRvIIIxCD3 can potently activate T cells in vivo to achieve significant antitumor 
effects against EGFRvIII-expressing tumors in the CNS.  
4.4 Discussion 
It has been widely-demonstrated that bscAbs of the BiTE class can be used to 
generate potent T-cell immune responses against tumors outside the CNS. Importantly, 
findings in the present study demonstrated that similar responses may be achieved 
against established tumors in the brain.  An additional advance reported here is the 
novel targeting of EGFRvIII with BiTE technology, making bscEGFRvIIIxCD3 the first 
molecule of its kind to target tumors specifically without cross-reactivity against 
antigens expressed normal tissues. 
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In general, bscAbs designed to redirect the immune system against cancer have 
an extensive history that has been thwarted by several shortcomings.  While some 
alternative bscAb constructs have resulted in prohibitive toxicity due to nonspecific T-
cell activation, others have been hampered by low potency, in many cases requiring 
extremely high E:T ratios and high concentrations of the therapeutic agent, as well as T-
cell prestimulation or costimulation in order to achieve acceptable preclinical efficacy 
(Choi et al., 2011).  By comparison, our study demonstrates that bscEGFRvIIIxCD3 has 
the ability to safely and specifically mediate antitumor responses that are both dose-
dependent and efficacious at low E:T ratios (2.5:1), without the need for additional T-cell 
stimulation.  Indicating its potency, a cumulative dose of just 5 μg (~0.25 mg/kg) 
bscEGFRvIIIxCD3 in vivo was sufficient to significantly prolong survival in mice with 
EGFRvIII-expressing tumor.  Notably, this dose is roughly equivalent to 0.02 mg/kg for 
the average 60 kg adult (Reagan-Shaw et al., 2008); by stark contrast, recommended 
therapeutic doses of currently approved antitumor mAb antibodies range from 2 mg/kg 
(Herceptin) (Slamon et al., 2001) to up to 10 mg/kg (Avastin) (Hurwitz et al., 2004), 
highlighting the potential for vast improvement over currently available antibody 
treatments for solid tumors.  
Previous studies have established that bscAbs of the BiTE class potentiate 
antitumor immune responses solely in the presence of cognate antigen expression by 
target cells (Choi et al., 2011).  This is partly due to the fact that the soluble anti-CD3 
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scFv moiety alone is not in itself directly tumoricidal, nor does it elicit functional T-cell 
activation or cytokine release compared to its cross-linking mAb counterparts (Le Gall et 
al., 2004).  As such, our in vitro and in vivo data corroborate that bscEGFRvIIIxCD3 is 
indeed dependent on target-cell EGFRvIII surface expression since bscEGFRvIIIxCD3 
did not mediate appreciable antitumor effects in the absence of EGFRvIII expression on 
matched tumor cell lines.  Furthermore, the need for dual-specificity was confirmed by 
the absence of antitumor activity both when using a control bscAbxCD3 and upon 
EGFRvIII-specific blockade with cognate PEPvIII peptide.  Importantly, these data also 
support peptide blockade as a useful strategy to eliminate unintentional T-cell activation 
against normal tissues; given our findings, it may even be reasonable to create larger 
peptide constructs designed to not enter the CNS—such molecules would in theory 
reduce systemic toxicity, while permitting intracerebral efficacy of antibody-redirected 
T-cell therapies that otherwise cause toxic side-effects due to promiscuous activity 
against peripherally expressed antigens. 
One unexpected finding in our study is the ability for systemically administered 
bscEGFRvIIIxCD3 to treat tumors in the CNS.  To date, several attempts have been made 
to validate immunotherapy as a viable treatment modality for tumors in the brain; 
however, in the great majority of published studies, beneficial antitumor immune 
responses have been limited to animal models in which vaccines were administered 
prior to tumor challenge.  By contrast, it has generally been difficult to demonstrate 
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successful treatment of intracerebral tumors following implantation, a fact which may 
partially explain the consistently poor clinical translation of immune-based interventions 
for patients with high-grade glioma.  Such considerations should be taken into account 
when interpreting the results of the present study, in which survival advantages were 
observed in the setting of even late-stage, well-established tumors.  These results 
provide evidence that bscEGFRvIIIxCD3 may be considerably more effective upon 
clinical translation than other strategies that have been tested in animal models of tumor 
challenge.  
Due to longstanding notions of immune-privilege in the brain, previous studies 
of bscAbs for CNS malignancies have been limited to intralesional treatment in vivo, and 
have not been tested for efficacy by systemic administration as reported in the present 
study (Grosse-Hovest et al., 2005). However, a growing body of evidence supports that 
EGFRvIII-specific molecules may possess a special ability to accumulate in tumor tissue 
located in the brain, and that this phenomenon may be attributed in part to exclusive 
expression of the EGFRvIII mutation in malignancy.  Due to their greatly reduced 
molecular weight, bscAbs of the BiTE class may prove even more efficient in their ability 
to localize intracerebrally, and studies are currently underway to further investigate this 
possibility.  Moreover, although CNS access is certainly limited to some degree, the 
relative potency of the BiTE platform at extremely low doses suggests that only small 
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amounts may actually need to reach the tumor in order to mediate significant 
therapeutic effects.  
We also observed in our study that therapeutic effects of bscEGFRvIIIxCD3 were 
associated with the accumulation of immune cells in the CNS. It has been previously 
shown that activated T lymphocytes have the ability to penetrate the blood-brain barrier 
(BBB) under even normal physiological conditions (Engelhardt and Ransohoff, 2005). 
While the focus of this literature has been dominated by CD4+ T cells—likely due to their 
involvement in neuroinflammatory disease—more recent reports show that CD8+ T cells 
also traffic into the brain and that this activity is mechanistically dependent on major 
histocompatibility (MHC) class I antigen presentation on cerebral endothelium (Galea et 
al., 2007). Interestingly, it has also been shown that EGFRvIII and other oncoproteins can 
be presented on the luminal surface of cerebral endothelial cells via microvesicular 
transfer (Al-Nedawi et al., 2009, Koga et al., 2005).  Because bscAbs like 
bscEGFRvIIIxCD3 have the ability to activate T cells without the need for conventional 
MHC recognition, it is conceivable that interaction between T lymphocytes and luminal 
antigen as mediated by a bscAb may offer a unique approach to recruiting polyclonal T 
lymphocyte populations past the BBB.  To our knowledge, the application of bscAb 
technology toward this end has not yet been suggested.  However, similar phenomena 
may partially explain results from early clinical trials wherein treatment with other 
BiTEs led to unexplained CNS side-effects, potentially due to the peripheral activation of 
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T cells and subsequent ability for these cells to enter the brain (Klinger et al., 2012, 
Bargou et al., 2008).  The implications of the discussion surrounding BiTEs, circulating 
lymphocytes and CNS localization are reviewed in greater detail in later chapters, and 
offer promising avenues for future study.   
While the primary goal of this work is to propel clinical translation of a novel 
treatment for patients with GBM, our observations also contribute to the growing body 
of literature regarding T-cell activation and its importance in antitumor immunity. 
Further investigation will be necessary to determine whether the therapeutic benefits 
here are recapitulated in human studies, and whether efficacy of bscEGFRvIIIxCD3 is 
impacted by standard-of-care therapies for GBM including radiation and temozolomide 
chemotherapy, a major side-effect of which is profound lymphopenia. These areas of 
research may best be approached in preclinical murine models with syngeneic tumors or 
in novel transgenic mice possessing T cells expressing human CD3 (Kuhn et al., 2011).  
Our group has recently rederived this useful mouse strain, preliminary data and 
potential uses of which will be reviewed in upcoming chapters of this dissertation.  
Almost certainly, the relevance of such studies will continue to broaden as this 
promising new drug class progresses through ongoing clinical trials. 
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5 Human Regulatory T cells Kill Tumor Cells Through 
Granzyme-Dependent Cytotoxicity Upon Retargeting 
with EGFRvIII BiTE 
A major mechanism by which human regulatory T cells (Tregs) have been shown 
to suppress and kill autologous immune cells is through the granzyme-perforin 
pathway.  However, it is unknown whether Tregs also possess the capacity to kill tumor 
cells using similar mechanisms.  In the last chapter, we demonstrated that bispecific 
antibodies (bscAbs) have emerged as a promising class of therapeutics that activate T 
cells against tumor antigens without the need for classical MHC-restricted TCR 
recognition.  In the current chapter, we will show that the same bscAb targeting the 
tumor-specific mutation of the epidermal growth factor receptor, EGFRvIII, has the 
capacity to redirect human Tregs to kill glioblastoma (GBM) cells.  This activity was found 
to be significantly abrogated by inhibitors of the granzyme-perforin pathway.  Notably, 
analyses of human primary GBM also displayed diffuse infiltration of granzyme-
expressing Foxp3+ T cells.  Together, these data suggest that despite their known 
suppressive functions, tumor-infiltrating Tregs possess potent cytotoxic mechanisms that 
can be co-opted for efficient tumor cell lysis.   
5.1 Introduction 
A major barrier that has impeded translation of efficacious immunotherapy is the 
inability to overcome profound immunosuppression associated with malignant disease 
(Zou, 2005).  Regulatory T cells (Tregs) in particular are thought to play a central role in 
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tumor escape from immune-mediated rejection.  One mechanism by which Tregs are 
known to suppress and even kill autologous immune cells is through the granzyme-
perforin pathway (Grossman et al., 2004a).  Despite this well-characterized cytotoxic 
capacity, whether Tregs can co-opt cytotoxic mechanisms to kill tumor cells has yet to be 
evaluated.   
T-cell-activating bispecific antibodies (bscAbs)—particularly those of the 
bispecific T-cell engager (BiTE) subclass—represent a new therapeutic strategy that has 
the potential to treat even bulky, invasive disease (Bargou et al., 2008).  As reviewed in 
detail in previous chapters, BiTEs are tandem single-chain molecules that possess dual 
specificity for tumor-associated surface antigens and the CD3 complex on T cells, which 
allows them to divalently bind and afford potent, specific target cell lysis (Choi et al., 
2011).  Because CD3 is universally expressed among T cells, BiTEs have the theoretical 
capacity to redirect and activate even Tregs that are elevated and present in tumors of 
patients with cancer.   
Among the few known tumor-specific antigens, perhaps the most widely-
characterized is the truncated mutant epidermal growth factor receptor variant type III 
(EGFRvIII).  EGFRvIII is a constitutively activated tyrosine kinase that is frequently 
expressed on the surface of GBM and other common neoplasms but is completely absent 
from healthy tissues (Choi et al., 2009).   
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In this chapter, we demonstrate that the EGFRvIII-specific BiTE, 
bscEGFRvIIIxCD3, successfully redirects highly-purified Tregs and activates them in the 
presence of tumors expressing EGFRvIII.  Despite their known suppressive properties, 
Tregs efficiently lysed EGFRvIII-expressing GBM in vitro upon redirection and activation 
with bscEGFRvIIIxCD3.  This activity was found to be dependent on the granzyme-
perforin pathway.  Immunohistochemistry (IHC) analysis from human primary GBMs 
also displayed diffuse infiltration of activated, granzyme-producing Foxp3+ cells, 
suggesting that Tregs with potent effector functions may already be present in tumors 
even under natural conditions. 
Previous efforts to enhance antitumor immunity via Treg depletion have been 
limited, in part due to an inability to efficiently eliminate suppressive cells that infiltrate 
tumor tissue (El Andaloussi et al., 2006).  Alternatively, our data suggest that BiTEs may 
actually convert suppressive Tregs into effector cells that possess great cytotoxic potential.  
These findings not only highlight a new mechanism by which BiTEs may circumvent 
certain aspects of Treg-mediated suppression, but also have broader implications with 
regard to the natural functional role of activated, tumor-infiltrating Tregs that express 
granzyme and perforin in the tumor microenvironment.   
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5.2 Materials and Methods 
5.2.1 Tumor Cell Lines and Reagents 
The human glioma cell line U87MG and its subline U87MG.ΔEGFR, which 
expresses EGFRvIII, are described elsewhere (Nishikawa et al., 1994).  Characterization, 
production and purification of bscEGFRvIIIxCD3 as well as control antibody constructs 
were performed as previously described by us (Choi et al., 2013).  Antibodies to CD4 
(RPA-T4), CD25 (M-A251), CD69 (L78), CD152 (BNI3), Granzyme A (CB9), Granzyme B 
(GB11) and Perforin (δG9) were purchased from BD Biosciences.  Anti-FoxP3 antibody 
(PCH101) and the Foxp3 Staining Buffer Set were purchased from eBioscience and 
intracellular staining was performed according to manufacturer instructions.  
Antibodies against human FoxP3 (259D, BioLegend) and granzyme B (Cat No. ab4059) 
were used for immunohistochemical staining. 
5.2.2 Treg Isolation and Preparation 
All human samples were obtained at Duke University Medical Center from 
individuals who had given written, informed consent.  Human PBMCs were prepared 
by density gradient centrifugation from buffy coats of healthy donor leukaphereses.  
Highly purified regulatory T cells were isolated from PBMCs by magnetic separation 
using the CD4+CD25+CD127dim/- Regulatory T Cell Isolation Kit II and autoMACS 
Separator (Miltenyi Biotec) according to manufacturer instructions.  Following isolation, 
purity was confirmed by flow cytometric analysis to be between 90 to 95% 
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(CD25+Foxp3+).  In certain experiments using preactivated cells, purified Tregs were 
activated and expanded with the Treg Expansion Kit (Miltenyi Biotec) at a MACSiBead 
Particle-to-Treg ratio of 4:1 according to manufacturer instructions.  Cells were expanded 
in the presence of recombinant interleukin 2 (rIL-2) at 500 U/mL for a maximum of 14 
days in the absence of rapamycin and were maintained at a purity between 90 to 95% 
(CD25+Foxp3+) (Efimova and Kelley, 2009).  Following isolation and expansion, Tregs were 
verified for their ability to suppress proliferation of responder cells in vitro as previously 
described (Koristka et al., 2012). 
 
Figure 35:  Magnetic bead sorting yields Treg purity greater than 95% determined by 
phenotypic markers, FoxP3 and CD127. 
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5.2.3 In Vitro Activation and Functional Assays 
Activation, proliferation, cytokine secretion and measures of specific lysis were 
performed as previously described by us (Choi et al., 2013).  For inhibition of the 
granzyme-perforin axis, concanamycin A (CMA, 100 nM; Sigma), Granzyme B Inhibitor 
I (Z-AAD-CMK, 50 μM; Calbiochem), or ethylene glycol tetraacetic acid (EGTA, 4 mM; 
Calbiochem) was added to each well in a total volume of 200 μL.  Blockade of FasL- and 
TRAIL-mediated apoptosis was carried out with antibody clones NOK-1 (25 μg/mL; BD 
Biosciences) and RIK-2 (25 μg/mL; BD Biosciences), respectively.  Where noted, 
supplemental rIL-2 at 1000 U/mL was added to purified, previously-unstimulated Tregs 
during culture in order to maintain their suppressive function (Barron et al., 2010). 
5.2.4 Immunohistochemistry 
Tissues for immunohistochemical analysis were derived from human brain 
tumor biopsy material.  Paraffin-embedded tissues were fixed, cut into 5 μm sections, 
mounted on glass slides and subjected to primary and secondary staining using the 
MACH 2 Double Stain 1 polymer detection kit (Biocare Medical) according to 
manufacturer instructions.  Diaminobenzidine (DAB) and AminoEthyl Carbazole (AEC) 
were used to detect granzyme B and Foxp3, respectively. 
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5.2.5 Statistical Analysis 
Groups were compared using a two-sample two-tailed t-test and statistical 
significance was determined at a value of P < 0.05.  
5.3 Results 
To investigate whether bscEGFRvIIIxCD3 possesses the ability to activate Tregs, 
purified CD4+CD25+CD127dim/- Tregs were cocultured with glioma cells expressing 
EGFRvIII (U87MG.∆EGFR) and bscEGFRvIIIxCD3.  Tregs were also cocultured with 
matched malignant glioma cells that do not express EGFRvIII (U87MG) to exclude the 
possibility that the CD3-binding portion of bscEGFRvIIIxCD3 alone was sufficient for 
activation.  After 48 hours of coculture, T cells were harvested and examined for surface 
and intracellular activation markers.  Expression of surface activation makers CD69 and 
CD25 were significantly elevated on Tregs stimulated by bscEGFRvIIIxCD3 specifically in 
the presence of U87MG.∆EGFR.  Although Tregs are known to constutively express 
elevated Foxp3 and CTLA-4, activation with bscEGFRvIIIxCD3 led to even greater 
expression of these markers as well, further indicating a favorable sign of activation 
(Miyao et al., 2012, Wing et al., 2008).   
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Figure 36:  EGFRvIII BiTEs activate Tregs to upregulate surface activation makers in the 
presence of EGFRvIII-expressing tumor in vitro. 
Purified CD4
+
CD25
+
CD127
dim/-
 Tregs express elevated levels of activation markers CD69, 
CD25, Foxp3 and CTLA-4 in response to bscEGFRvIIIxCD3 specifically in the presence 
of EGFRvIII-expressing tumors.   
 
Sorted Tregs produced greatly reduced levels of inflammatory cytokines when 
compared to CD4+CD25- helper T cells in response to stimulation with 
bscEGFRvIIIxCD3.  In addition, of the cytokines produced, redirected Tregs appeared to 
have a predominately immunosuppressive functional profile when analyzed by 
standard cytometric bead array analysis.   
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Figure 37:  Tregs produce significantly lower levels of inflammatory cytokines 
compared to responder helper T cells in response to bscEGFRvIIIxCD3. 
(Left panel) Supernatants from wells containing U87MG.ΔEGFR, bscEGFRvIIIxCD3 and 
CD4+CD25+127dim/- Tregs contained significantly lower levels inflammatory cytokines 
compared to wells in which responder cells consisted of purified CD4+CD25- helper T 
cells (Th).  Control bars represent cytokine secretion of Tregs in the presence of non-
specific BiTE and U87MG.ΔEGFR.  All tests were performed in triplicate wells and 
independently repeated.  Horizontal bars represent a statistical significance of P < 0.05. 
(Right panel) This same data is presented normalized with respect to cytokines secreted 
by Th cells. 
   
 
Figure 38:  Cytokine profile of redirected Tregs demonstrates secretion of IL-10 in the 
presence of EGFRvIII BiTE and target cells expressing EGFRvIII. 
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Moreover, Tregs also remained refractory to proliferative signals in response to 
stimulation under these conditions, indicating that activation via bscEGFRvIIIxCD3 
appears to have similar effects on Treg activity that would be generally expected with 
standard methods of T-cell stimulation in vitro. 
 
Figure 39:  Tregs remain refractory to proliferative signals in response to 
simulation through EGFRvIII BiTE. 
Proliferation of Tregs and Th in response to bscEGFRvIIIxCD3 and solid phase EGFRvIII 
as measured by 3H-thymidine incorporation demonstrates that proliferative defects in 
the Treg compartment persist following activation with bscEGFRvIIIxCD3.  All tests 
were performed in triplicate wells and independently repeated.  Horizontal bars 
represent a statistical significance of P < 0.05 
 
As a class of therapeutics, bscAbs are known to bypass a number of tumor-
associated mechanisms of immune escape by allowing effector T cells (Teffs) to detect and 
eliminate tumor cells without the need for conventional antigen-presentation and MHC-
peptide recognition.  Based on recent findings that increasing the strength of cognate 
antigen stimulation may actually allow Teffs to overcome the suppressive effects of Tregs 
on cytotoxicity (Gobel et al., 2012), we sought to determine whether the EGFRvIII-
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specific bscAb would similarly redirect Teffs against target tumor cells despite the 
presence of suppressive Tregs in vitro.  In a standard 51Cr release assay using freshly 
thawed, unstimulated human PBMC as effector cells, incubation with bscEGFRvIIIxCD3 
led to the efficient lysis of EGFRvIII-expressing tumor cells as previously described by 
us.  Interestingly, we found that the addition of Tregs (effector:Treg, 1:1) did not negatively 
impact redirected cytotoxicity but instead significantly enhanced overall specific lysis 
against EGFRvIII-expressing tumor cells in vitro.   
 
Figure 40:  Tregs do not suppress effector cell lysis against EGFRvIII-expressing glioma 
upon redirection with EGFRvIII BiTE. 
Standard 51Cr-release demonstrates specific lysis of U87MG.∆EGFR over U87MG by 
unstimulated human PBMCs and BiTE that is significantly elevated in the presence of 
Tregs at an effector to Treg ratio of 1:1.  All tests were performed in triplicate wells and 
independently repeated.  Horizontal bars represent a statistical significance of P < 0.05. 
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Although a number of mechanisms could account for this phenomenon, certainly 
one possible explanation is that Tregs may actually be acting as cytotoxic effectors against 
tumor cells in the presence of bscEGFRvIIIxCD3.  To formally test this, we sought to 
determine whether highly purfied Tregs alone could mediate measureable specific lysis 
against tumor cells.  Indeed, when using purified, previously unactivated Tregs as effector 
cells in vitro, we found that addition of EGFRvIII-specific BiTE yielded significant 
antitumor effects against target cells expressing EGFRvIII.  Interestingly, the magnitude 
of cytotoxicty observed by purified Tregs alone approximated the additional cytotoxicity 
that had been observed upon addition of Tregs, notated by brackets in the respective 
figures 
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Figure 41:  Tregs acquire the ability to directly kill tumor cells upon redirection with 
the EGFRvIII BiTE. 
When purified, CD4+CD25+CD127dim/- Tregs alone were also observed to lyse target 
EGFRvIII-expressing tumor cells upon redirection with BiTE (18 hours; E:T ratio 20:1; 
[BiTE] 10 µg/mL; rIL-2).  Vertical bracket illustrates comparable magnitudes of 
cytotoxicty observed by purified Tregs alone with additional cytotoxicity that had been 
observed upon addition of Tregs.  All tests were performed in triplicate wells and 
independently repeated.  Horizontal bars represent a statistical significance of P < 0.05. 
 
Upon activation, Tregs are known to possess sigificant suppressive capacity, at 
least in part due to their ability to efficiently induce high levels of granzyme B 
expression (Efimova and Kelley, 2009).  The perforin-granzyme pathway is a well-
characterized mechanism by which Tregs are known to actually kill effector cells, thereby 
inhibiting effective immune responses (Grossman et al., 2004a, Grossman et al., 2004b).  
However, because the EGFRvIII-specific BiTE has the theoretical potential to activate 
 125 
and redirect all cells expressing CD3—including even suppressive Tregs—we 
hypothesized that this molecule might also coopt Tregs to kill EGFRvIII-expressing tumor 
cells, specifically by redirecting their perforin-granzyme-mediated mechanisms of 
immune suppression to instead destroy target cancer cells. 
To test this hypothesis, we first designed experiments to determine the impact of 
bscEGFRvIIIxCD3 on the expression of perforin and granzymes in Tregs.  PBMCs were 
gated on CD4+CD25+Foxp3+ cells prior to flow cytometric analysis for intracellular 
perforin and granzyme expression.  While unactivated Tregs expressed only low levels of 
perforin, granzyme A (GrA) and granzyme B (GrB), Tregs activated in the presence of 
bscEGFRvIIIxCD3 and EGFRvIII-expressing target cells exhibited marked upregulation 
of the perforin-granzyme pathway.   
Importantly, consistent with what has been shown for in the setting of activation, 
Tregs continued to supress responder cell proliferation in vitro, indictating retention of 
their typical properties following engagement with the EGFRvIII BiTE. 
 
 126 
 
Figure 42:  Tregs activated by bscEGFRvIIIxCD3 exhibit marked upregulation of the 
perforin-granzyme pathway. 
Human PBMCs were incubated in the presence of U87MG (vIII-, top) or U87MG.ΔEGFR 
(vIII+, bottom) and bscEGFRvIIIxCD3, harvested and stained for flow cytometric 
analysis.  CD4+ cells were isolated and gated for high CD25 and Foxp3 expression and 
then analyzed for Perf, GrA and GrB expression with positivity determined by isotype 
control.  Plots are representative of at least three repeated experiments. 
 
 
Figure 43:  Redireted Tregs suppress responder cell proliferation followed by TCR 
engagement by bscEGFRvIIIxCD3. 
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Given that even previously unactivated Tregs yielded antitumor effects in vitro 
with presumeably lower levels of perforin and granzyme expression, we sought to 
determine whether preactivated Tregs—which are actually thought to more closely 
resemble highly suppressive Tregs associated with tumors (Gobert et al., 2009)—also 
possessed the capacity to kill tumor cells.  Indeed, our data demonstrate that 
preactivated Tregs efficiently lyse target cells expressing EGFRvIII when redirected with 
EGFRvIII-specific BiTE.  Importantly, this effect was not detected in the presence of a 
nonspecific control bscAb or Tregs alone, further demonstrating the specifity of this 
cytolytic activity. 
 
Figure 44:   Activated Tregs possess enhanced cytotoxic activity against EGFRvIII-
expressing tumor in the presence of EGFRvIII BiTE. 
Upon redirection with bscEGFRvIIIxCD3, but not a non-specific control bscAb (Control), 
activated Tregs demonstrate enhanced lysis against EGFRvIII-expressing tumor 
(Treg:target, 20:1; incubation time 18 hours; [BiTE] 10 µg/mL).  All tests were performed 
in triplicate wells and independently repeated.  Horizontal bars represent a statistical 
significance of P < 0.05. 
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Moreover, redirected Treg-mediated lysis was shown to be actually dependent on 
the perforin-granzyme pathway, since cytotoxicity was not impacted by TRAIL or FasL 
blockade, but significantly abrogated in the presence of previously-characterized 
inhibitors of perforin- and granzyme-mediated cytotoxicity. 
 
Figure 45::  Treg-mediated antitumor effects are dependent on the granzyme-perforin 
pathway. 
Specific lysis against target tumor cells expressing EGFRvIII is not significantly inhibited 
by blockade of Fas ligand- and TRAIL-mediated apoptosis but is significantly abrogated 
by partial inhibitors of the granzyme-perforin pathway, Z-AAD-CMK, EGTA and CMA.  
Pairwise comparisons with respect to Treg, BiTE and inhibitors of the granzyme-perforin 
pathway were made.  All tests were performed in triplicate wells and independently 
repeated.  Horizontal bars represent a statistical significance of P < 0.05. 
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Adding clinical relevance to these findings, infiltrating Foxp3
+
 Tregs in human 
glioma samples were actually found to coexpress detectable levels of granzyme B by 
immunohistochemical analysis (Figure 4C), suggesting that activated Tregs with potent 
effector functions may be present within GBMs, and could potentially serve as effector 
cells upon infusion with T-cell-engaging bscAb therapies in vivo.   
 
Figure 46:  IHC analysis of human GBM for Tregs and granzyme B. 
IHC analysis of human GBM shows diffuse infiltration of Foxp3+ Tregs (AEC) expressing 
detectable levels of granzyme B (DAB). 
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5.4 Discussion 
In light of recent findings demonstrating that Tregs may actually be required for 
the priming of high-avidity CD8+ T-cell responses (Pace et al., 2012), innovative methods 
to reappropriate the Treg compartment without ablating these cells completely could 
provide an attractive alternative to currently available depletive strategies.  As such, we 
have provided for the first time evidence and a mechanism by which Tregs might be 
redirected to kill tumor cells through engagement with a bscAb.  One previous study 
has explored the impact of bscAbs on Tregs, and demonstrated that bscAb-mediated 
activation of Tregs suppresses effector cell proliferation and abrogates antitumor efficacy 
(Koristka et al., 2012).  However, the direct effects of bscAb-redirected Tregs on target 
tumor cells were not discussed.  Furthermore, because their work employed the use of 
rapamycin to expand Tregs ex vivo—an additive which is known to completely suppress 
GrB expression in Tregs (Efimova and Kelley, 2009)—it may ultimately not be feasible to 
directly compare the results of our studies.  In the current study, redirected cytotoxicity 
was dependent on the presence of bscEGFRvIIIxCD3; though, it may be reasonable to 
suspect that similar results might be observed upon even endogenous TCR-specific 
engagement of granzyme-producing Tregs present in the tumor microenvironment.  
Importantly, this work opens a new discussion regarding such potential mechanisms, 
which will need to be further explored across broader areas of autoimmunity and 
immunotherapy where Treg biology is relevant.   
 131 
6 Human CD3ε Transgenic Mice Provide a Novel 
System for Evaluation of Bispecific Antibodies 
6.1 Introduction 
As detailed in previous chapters, to test bscEGFRvIIIxCD3 in vivo we chose an 
NSG mouse model, which has the distinct advantage of evaluating drug candidates in 
an animal system using human tumor tissue, with the potential to directly translate the 
therapeutic molecule of interest into clinical studies.  Indeed, initial preclinical studies of 
the first-in-class CD19-targeted BiTE now in clinical trials were originally performed in 
immunocompromised mouse models, the main limitations of which have been 
described elsewhere (Dreier et al., 2003).  Briefly, one of the major drawbacks of this 
approach includes the need to supply human effector T cells, which is further 
compounded by the fact that human cells often have a limited functional half-life in the 
murine background.  However, taking into account these considerations, it may be 
reasonable to conclude that our results in fact underestimate the full potential of 
bscEGFRvIIIxCD3, especially given that—in a realistic clinical scenario—circulating 
polyclonal T cell populations should be present in great number and persistent 
throughout the body.  
Regardless, although early results against xenografts certainly provide evidence 
of efficacy, the species-restricted activity of our BiTE—which is reactive only with 
human lymphocytes—not only impedes proper optimization for safety and efficacy, but 
also limits the pursuit of numerous mechanistic studies that would only be 
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appropriately examined in hosts with endogenous immunity.   Importantly, other T-cell 
activating antibodies have historically met with unforeseen toxicity when translated in 
early clinical trials, at least in part due to the lack of appropriate immunocompetent 
rodent models possessing surface molecules of equivalent binding affinities and 
function to those found in humans (Attarwala, 2010).    
Thus, the challenge of evaluating human-specific agonist antibodies in animal 
models has represented a major bottleneck in the translation of immune-based therapies.  
To address this issue, transgenic mice have recently been engineered to express human 
CD3 on the surface of T lymphocytes, thus providing a much-needed platform for 
preclinical evaluation of therapeutics (Kuhn et al., 2011).  It has been previously 
suggested that these mice would provide the ideal system for preclinical evaluation of 
BiTEs (Thompson et al., 2009), though the advantages of using this animal model have 
not yet been realized to date.  When heterozygous, CD3 transgenic mice are reported to 
be immunocompetent and possess fully functional peripheral T cells that respond to 
stimulation through both human and murine CD3 (Wang et al., 1998, Weetall et al., 
2002).  Given the promise of our EGFRvIII targeted BiTE molecule in xenogeneic models, 
we decided to re-derive this valuable mouse colony to perform studies that would 
support relevant preclinical development.  The current chapter will report preliminary 
data obtained to date in this model, and suggest potential avenues of study that may be 
pursued using this preclinical system. 
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6.2 Materials and Methods 
6.2.1 Mice and Tumor Cell Lines 
C57BL/6J were obtained from Jackson Laboratories.  CD3 transgenic mice 
(tgε300) were transferred to Duke Division of Laboratory Animal Resources as embryos 
as a kind gift from Dr. Cox Terhorst (Beth Israel Deaconess Medical Center) and 
implanted into surrogate mothers for rederivation.  Mice were maintained and bred 
under pathogen-free conditions at Duke University Medical Center (DUMC).  All animal 
experiments were performed according to protocols approved by the Duke University 
Institutional Animal Care and Use Committee (IACUC). 
6.2.2 Temozolomide Preparation 
TMZ (Temodar, Schering-Plough and Best Pharmatech) was dissolved in a 
solution of 85% saline and 15% dimethyl sulfoxide (DMSO). Mice were weighed and 
injected intraperitoneally with a calculated dose daily for 5 days as indicated.  
6.2.3 Peripheral Blood Draws and Complete Blood Counts 
Retro-orbital eye bleeding was used to collect 50-100 μl blood into heparinized 
tubes for complete blood count (CBC) and flow cytometric analyses. CBCs were 
performed by the Duke Veterinary Diagnostic Laboratory on a VetScan HM5 
Hematology Analyzer (Abaxis Inc). 
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6.2.4 Flow Cytometric Analysis 
Antibodies to CD3 (145-2C11), CD4 (L3T4), CD8 (53-6.7), and CD16/32 (2.4G2), as 
well as appropriate isotype controls, were obtained from BD Pharmingen (San Diego, 
CA). Anti-Foxp3 (FJK-16s) was obtained from eBioscience (San Diego, CA).  Whole 
blood obtained by retro-orbital bleeding was analyzed for T cells, CD8+ T cells and CD4+ 
T cells as follows: samples were incubated with a cocktail of antibodies in 150 μL FACS 
buffer in the dark for 15 minutes at room temperature.  Red blood cells (RBCs) were 
lysed and cells were fixed using 1 ml 1X BD FACS Lysing Solution (BD Bioscience, Cat# 
349202) and incubated overnight at 4 ºC.  Cells were then washed and re-suspended in 
2% paraformaldehyde and submitted to flow cytometry analysis.  
6.3 Results 
6.3.1 Characterizing the Human CD3ε Transgenic Mouse Model 
We first sought out to determine whether splenocytes from our CD3ε transgenic 
mice (C57BL/6J background) expressed human CD3 following the rederivation 
procedure.  These mice were previously reported to express both mouse and human 
CD3ε on the surface of circulating T cells, and indeed, we found this to be the case.  
Whereas splenocytes from wild-type C57BL/6J demonstrated only murine CD3ε 
expression when co-stained for both human and murine CD3ε by FACS, almost all 
splenocytes from transgenic mice that were positive for murine CD3ε were shown to 
express surface human CD3ε as well.   
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Figure 47:  Analysis of surface CD3ε expression in splenocytes from human CD3ε 
transgenic mice. 
Splenic single cell suspensions were examined by FACS analysis for both human and 
murine CD3ε using antibody clones OKT3 and 145-2C11, respectively. 
 
Following our detection of human CD3ε surface expression in splenocytes of 
CD3ε transgenic mice, we performed experiments to determine the functional properties 
of the human CD3ε transgene gene product in murine T cells in vitro.  Towards this end, 
we isolated splenocytes and tested several metrics of function in response to activating 
signals through solid phase anti-human or anti-mouse CD3-specific agonistic antibodies, 
OKT3 and 145-2C11, respectively.  In accord with previously published data regarding 
this mouse strain, we found that our rederived, transgenic mice possessed T cells that 
were capable of functional responses upon appropriate stimulus.  Importantly, while 
wild-type splenocytes were solely responsive to CD3ε engagement by 145-2C11,  
splenocytes from human CD3ε transgenic mice responded to stimulation with both 145-
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2C11 and OKT3, as measured by assays of proliferation as well as secretion of 
inflammatory cytokines TNF-α and IFN-γ.   
 
Figure 48:  Proliferative responses of wild-type and CD3ε transgenic splenocytes 
activated by solid phase anti-CD3 agonistic antibodies. 
 
Figure 49:  CBA analysis of supernatants from wild-type and CD3ε transgenic 
splenocytes activated by solid phase anti-CD3 agonistic antibodies. 
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6.3.2 Ongoing Studies to Evaluate BiTEs in the Context of 
Lymphodepletive Chemotherapy 
One factor that may play a significant role in the ability of BiTEs to successfully 
treat brain tumors is the availability of circulating effector T cells.  This is of particular 
concern in patients with glioma, since a prominent side effect of current standard-of-care 
temozolomide chemotherapy is the induction of profound lymphopenia.  Given that 
BiTE-mediated antitumor efficacy is known to rely on the redirection of T cells, it is 
reasonable to speculate that depletion of this cellular compartment may compromise the 
efficacy of the BiTE therapeutic platform.  This line of reasoning is a classic illustration of 
how immunocompetent preclinical models—such as the CD3ε transgenic system—are 
essential to appropriately evaluate immune-modulatory therapies, given that xenograft 
systems cannot accurately reflect the physiological milieu of an immune replete host, 
especially during recovery from lymphodepletive chemotherapy.   
In our group, we have recently developed murine doses of temozolomide that 
are designed to recapitulate clinically relevant chemotherapy-induced lymphodepletion 
in the C57BL/6J mouse model.   Our data demonstrated that treatment with a non-
myeloablative temozolomide dose (60 mg/kg x 5 days) leads to a significant T-cell 
lymphopenia in mice.  Flow cytometric analysis of peripheral blood revealed that both 
CD4+ and CD8+ were profoundly depleted immediately after cessation of temozolomide 
administration, and that these cells either remained depressed or experienced protracted 
recovery over the course of 30 days.   
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Figure 50:  Temozolomide chemotherapy results in depletion of circulating T cells. 
To evaluate the impact of temozolomide chemotherapy on circulating T cells, C57BL/6 
mice (n = 5) were treated with vehicle or temozolmide (60 mg/kg x 5 days).  Mice were 
bled retro-orbitally on days 7, 14 and 28 after termination of TMZ administration and 
submitted to flow cytometry analysis.  Absolute numbers per µL of blood were 
calculated using Flowcount beads (Beckman Coulter). 
 
6.4 Discussion 
Although we have not yet formally evaluated the efficacy of BiTEs in the context 
of an immune competent host, there are several potential advantages to developing an 
murine model that could eventually be applied towards this end.  For example, in 
addition to the fact that lymphodepletion may antagonize BiTE-mediated antitumor 
responses in vivo, emerging hypotheses also posit that  peripheral depletion of otherwise 
abundant CD3+ cells may actually promote the intracerebral accumulation of BiTEs at 
tumor sites in the brain.  This theory is based on the idea that a vast population of 
circulating CD3-expressing cells may otherwise sequester BiTE molecules in the 
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periphery, hampering their ability to localize to tumors in the brain at therapeutically 
relevant quantities.  Since BiTEs have been shown to mediate antitumor efficacy even at 
exceedingly low effector-to-target ratios, lymphodepletion may provide a useful 
strategy to promote intracerebral localization of BiTEs while maintaining an acceptable 
level of effector T-cell activity in vivo.   
Overall, we believe that experiments performed in the syngeneic system will at 
least corroborate our results obtained in the xenograft model, and have already 
mentioned reasons why it may actually be superior in terms of achieving therapeutic 
effects.  Conversely, however, we may ultimately find that our immunocompetent 
model may yield less dramatic results, in which case the CD3ε transgenic system could 
still be leveraged to explore variables that may improve our strategy for translation and 
clinical trial design.  For instance, whereas EGFRvIII BiTE localizes rapidly and 
efficiently to intracerebral xenograft tissue, this level of accumulation may not be 
achieved when tumor and stroma cells grow together in the syngeneic setting.  If this 
occurs, we could explore the opportunity to enhance intracerebral localization of both 
circulating T cells and BiTE—a subject that is discussed in greater detail in the next 
chapter of this dissertation—or attempt local injection through existing preclinical 
models of convection-enhanced delivery.  In addition, we can also further our 
understanding of the potential impact of immunosuppressive factors (e.g,. Tregs, myeloid-
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derived suppressor cells, cytokines) on BiTE-mediated activity, which can only be 
evaluated with any fidelity in the syngeneic, immunocompetent setting.  
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7 Early Clinical Translation of EGFRvIII BiTEs for 
Patients with Malignant Glioma 
As introduced briefly in previous chapters, in order for BiTEs to achieve their full 
potential in patients, both BiTEs and effector T cells will need to have access not only to 
areas of permeable, bulky tumor, but also to invasive areas of infiltrative tumor thought 
to reside beyond an intact BBB.  Importantly, substantial rationale exists to support that 
both BiTEs and BiTE-activated T cells may actually possess the unique ability to 
penetrate the BBB.  Fortunately, experiments designed to explore these phenomena are 
ideally suited to emerging phase 0/1 microdosing clinical trials, which enable 
pharmacokinetic assessment of novel therapeutics in humans, without the need to 
submit a Investigational New Drug (IND) application. 
7.1 Mechanisms by which BiTEs May Penetrate the Blood-Brain 
Barrier 
A novel therapeutic concept in this chapter is the hypothesis that BiTEs have the 
capacity to accumulate beyond the BBB by two potential mechanisms:  (1) BiTEs may 
“hitchhike” on activated T cells that are known to frequently enter and circulate through 
the CNS and (2) BiTE may accumulate in IC tumors due to the presence of a cognate 
“antigen-sink.”   
While circulating naïve T cells do not typically penetrate the CNS, activated T 
cells are known to traffic frequently past the BBB and perform routine immune 
surveillance in the CNS (Hickey et al., 1991).  Furthermore, it has previously been shown 
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that particles bound to the surface of antigen-specific T cells have the ability to localize 
to tumors and accumulate there (Cole et al., 2005).  Whether this mechanism could be 
used to enhance localization of a macromolecule like a BiTE has not been studied to 
date, but has potentially far-reaching consequences in the fields of BBB biology and 
therapeutic delivery.  Notably, it has also been shown that upon even natural 
stimulation in the periphery, T cells gain the ability to track into the CNS (Odoardi et al., 
2012).  Similarly, BiTEs may also play an important role in the localization and retention 
of effector T cells at IC sites.  Recent data have shown that BiTEs targeted against 
systemically-expressed antigens like CD19 lead to peripheral activation of effector-
memory T cells (Klinger et al., 2012, Bargou et al., 2008), which was temporally 
associated with subsequent unexplained, but transient, CNS side effects in multiple 
patients.  Consistent with this, our data demonstrate that in preclinical models, 
intravenous treatment with the EGFRvIII-specific BiTE results in the accumulation and 
diffuse infiltration of lymphocytes to intracerebral EGFRvIII-expressing tumors.  In 
contrast, this phenomenon was completely absent in mice receiving a phosphate-
buffered saline (PBS) vehicle control, suggesting that trafficking of T cells to the target 
EGFRvIII antigen was at least in part dependent on presence of the BiTE.  T cells thought 
to cause CNS symptoms in patients receiving the CD19 BiTE consisted largely of 
activated, effector-memory T cells, which are also known to be precisely the T-cell 
phenotype that is critical in an effective antitumor response; although such infiltrating T 
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cells did not naturally possess specificity to attack cells expressing tumor antigens in the 
CNS, an EGFRvIII BiTE would in theory have the ability of redirecting these highly-
activated T cells—that otherwise possess agnostic T-cell receptor (TCR) restriction—
against tumors in the brain. 
Another novel hypothesis that may play a role in the ability of BiTEs to 
accumulate past the BBB is dependent on the presence of an intracerebral antigen sink.  
This concept refers to the ability of an antibody to accumulate over time in the proximity 
of its cognate antigen, if and only if this cognate antigen is not also expressed in other 
tissues outside the CNS.  As described briefly in Chapter 1 , although access to the CNS 
is certainly limited to some extent, it has been known for some time that tiny amounts of 
peripherally circulating antibodies can in fact be detected in the CNS—between 0.1% to 
1% of that found in serum (Freund, 1930).  Thus in the absence of cross-reactivity with 
systemic antigens, it is thought that small amounts of highly-specific BiTE treatments 
may penetrate the CNS through a passive mechanism of diffusion, and be retained there 
over time to reach therapeutically relevant quantities.  This theory of a functional IC 
antigen sink is corroborated by studies in which infusions with radiolabeled monoclonal 
antibody specific for EGFRvIII demonstrated tumor-specific uptake and high levels of 
BBB penetration in patients with GBM (Scott et al., 2007a).  In addition, recent data has 
been published recent clinical trials, in which almost all patients who possessed potent 
humoral responses to an EGFRvIII peptide vaccine no longer expressed the EGFRvIII 
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tumor antigen in their tumors at recurrence (Sampson et al., 2010, Sampson et al., 2011).  
These data, along with the fact that BiTEs appear effective against invasive  intracerebral 
tumors (Choi et al., 2013) certainly suggest that a tumor-specific humoral response can 
mediate therapeutic effects at an intracerebral tumor site.  Importantly, the CD3 antigen 
present on circulating T cells should not provide a significant source of peripheral 
antigen in patients with GBM, given the profound lymphodepletion associated with 
standard-of-care temozolomide chemotherapy; however, formal evaluation of this 
potential phenomenon could be pursued, particularly in representative preclinical 
models such as the novel CD3ε transgenic system detailed in the previous chapter. 
 145 
 
Figure 51:  Mechanisms by which BiTEs may localize to intracerebral tumors. 
The systemic administration of an EGFRvIII BiTE results in its successful localization to 
EGFRvIII-expressing brain tumors and in the activation of T cells to sustain potent 
antitumor immune responses.  The EGFRvIII-targeting BiTE may gain access to the 
central nervous system on the surface of activated T cells or may accumulate 
independently, owing to specific interactions with the cognate EGFRvIII antigen on 
brain tumor cells.   
 
7.1.1 Cre-Inducible Transgenic Murine Models for the Study of 
Intracerebral Localization  
Although our previous experience supported that peripheral administration with 
EGFRvIII BiTE was sufficient to treat orthotopic glioma xenografts in vivo, we sought to 
validate that intracerebral localization would be maintained under even more stringent 
conditions.  Thus, we attempted to visualize BiTE molecules as they localized to an 
especially invasive, cancer stem-like GBM model that we feel closely recapitulates the 
BBB as it exists natural in the tumor microenvironment.  Using a cranial window model 
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followed by intravital in vivo confocal microscopy, we observed that intravenously 
administered, fluorochrome-labeled BiTE accumulated in EGFRvIII expressing 
intracranial tumors, but not in adjacent normal brain from the same animal.  
Importantly, appreciable localization was only observed over a 24 hour period, rather 
than in the time immediately following injection, implying that penetration of the BBB 
was limited in our model compared to what would be expected for peripheral tumors or 
“leaky” xenograft models that have been published elsewhere.  Based on these 
observations, there seems to be mounting support that EGFRvIII-targeted BiTEs have 
the capacity to successfully accumulate past the BBB to an intracerebral antigen sink.   
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Figure 52:  Intracerebral localization of BiTE to EGFRvIII-expressing glioma through 
cranial window. 
Following engraftment of EGFRvIII-expressing GBM, surgically implanted glass 
windows were used for chronic intravital microscopy.  After 10 days, mice were treated 
with intravenous EGFRvIIIxCD3 BiTE conjugated to Alexa-488.  In vivo images were 
then obtained with a fluorescent confocal microscope at 30 minutes and 24 hours in 
either areas of tumor (T) or normal brain (NB). 
 
As a brief aside, a number of preclinical models have also been developed that 
incidentally support the theoretical CNS antigen-sink hypothesis.  Perhaps most 
convincing are experiments in which diphtheria toxin (DT) was administered to rodents 
with Cre-inducible diphtheria toxin receptor (DTR) expression solely in 
oligodendrocytes (Buch et al., 2005).  Intraperitoneal DT injections in these mice led to 
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efficient intracerebral localization and myelin loss in the CNS.  Importantly, while DT 
(~60 kDa) is known to cross the BBB of humans through receptor-mediated endocytosis, 
this protein is conversely—restricted from the brains of rodents due to species specific 
restriction (Wrobel et al., 1990).  Because DTR is not naturally expressed murine tissues, 
the selective localization and ablation of oligodendrocytes in this model provides 
evidence that antigen-sinks may allow for accumulation of even larger protein 
molecules beyond the BBB.   
In order to formally explore mechanisms by which T cells or BiTEs may 
penetrate a fully intact BBB, this well-characterized Cre-inducible transgenic mouse 
model can also be used to drive expression of EGFRvIII in various murine tissues of 
interest.  The advantage of this model is ideal given that it permits anatomically-limited 
expression of an antigen while excluding any potential disruption of the BBB due to the 
presence of a tumor mass.  Although this type of mouse model has been previously 
described (Zhu et al., 2009), the use of this system to study antigen-specific localization 
of T cells and or antibody-based macromolecules would be novel and innovative.  These 
areas of future study, as well as those that may be performed in conjunction with human 
CD3ε transgenic mice, may yield useful preclinical data and mechanistic principle to 
inform future approaches to drug delivery and clinical trial design.  
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7.2 Phase 0/1 Microdosing Study of EGFRvIII BiTEs in Patients 
with Recurrent EGFRvIII+ Glioblastoma 
Microdosing is a recent mechanism endorsed by the FDA for the quicker access 
of new medicine and reduced attrition of translation at the later stages of preclinical 
drug development. The implementation of these studies was based on the need to 
address the discordance between major scientific advances and limited drug 
development. The concept of microdosing involves the use of extremely low doses of a 
drug to define the pharmacokinetic profile of the medication in human subjects, and this 
strategy is currently used by 15 of the 20 largest pharmaceutical companies in drug 
development (Tewari and Mukherjee, 2010).  Importantly, despite its promise, 
microdosing has been underutilized at academic centers to date.  
Early clinical trials testing the CD19-specific BiTE for patients with non-
Hodgkin’s B cell lymphoma achieved complete responses in patients with doses as low 
as 15 µg/m2/day over 1 week intervals.  Previously, several murine studies had 
demonstrated the potency of these constructs, which reported complete suppression of 
growth in subcutaneous tumor models at doses in the range of 1-10 μg/mouse/day over 
5 days (De Jonge et al., 1998, Kriangkum et al., 2001, Wuest et al., 2001, Flieger et al., 
2000).  Because we observed comparable responses to EGFRvIII BiTE in our preclinical 
models of intracranial tumor at doses approximately 10-fold greater than those observed 
in corresponding preclinical experiments for previous constructs, we estimate that 
therapeutically relevant human doses of the EGFRvIII BiTE will begin at approximately 
 150 
150 µg/m2/day, which is roughly equivalent to 4 μg/kg/day for the average 60 kg adult 
(Reagan-Shaw et al., 2008).  By stark contrast, recommended therapeutic doses of 
currently approved antitumor monoclonal antibodies range from an equivalent of 300 
μg/kg/day (Herceptin) (Slamon et al., 2001) to up to 700 μg/kg/day (Avastin) (Hurwitz et 
al., 2004), further highlighting the exquisite potency of the BiTE therapeutic platform. 
Given our encouraging results in preclinical models to date, our plan will be to 
pursue early human studies to determine the pharmacokinetic behavior of BiTEs and 
BiTE-activated T cells in a realistic clinical scenario.  Using the microdosing approach, 
we will apply positron emission tomography (PET) and single photon emission 
computerized tomography (SPECT-CT) imaging to assess biodistribution of 111In-labeled 
T lymphocytes and 124I-radiolabeled EGFRvIII BiTE in patients with recurrent, biopsy-
proven, EGFRvIII-positive GBM.  Although CNS access will certainly be limited to some 
degree, the relative potency of the BiTE platform at extremely low doses (Bargou et al., 
2008) suggests that only small amounts may actually need to reach the tumor in order to 
mediate significant therapeutic effects.  Importantly, human microdosing studies will 
provide a permissive regulatory environment that will allow an early assessment of 
potential toxicity and efficacy of this BiTE at low doses that can be feasibly 
manufactured in an academic environment.  
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7.2.1 Preparation of Clinical EGFRvIII BiTE Reagent to Enable Human 
Microdosing Studies 
Importantly, I have had the opportunity to work in a laboratory environment 
with a long history in the preparation, submission, and maintenance of investigator-held 
INDs, especially for monoclonal antibodies and immunoconjugates.  It would otherwise 
be unfeasible to propose the production of recombinant antibodies in large quantities 
necessary for a microdosing trial.  According to the FDA, Good Laboratory Practices 
(GLP) quality and procedures are acceptable for microdosed therapies, which are 
defined by a dose of no more than 30 nanomoles for protein products (equivalent to 150 
μg).  General preclinical toxicity studies are required, which consist of extended single 
dose toxicity in one species by intended route of administration, with accompanying 
hematology, clinical chemistry, necropsy, and histopathological data.  Briefly, cDNA 
encoding the BiTE will be cloned into an expression vector under the T7-promoter and 
expressed in E. coli. Protein is prepared from inclusion bodies by standard method and 
purified using metal affinity chromatography as outlined in Chapter 3.  In preparation 
for clinical studies, we will first prepare a master cell bank (MCB) expressing EGFRvIII 
BiTE.  Although GLP quality procedures are sufficient for microdosing studies, we plan 
to adhere to more stringent Quality Control (QC)/Quality Assurance (QA) procedures 
such as (1) testing the MCB to ensure the following: identity of cells, plasmid purity, and 
safety; (2) developing the fermentation in a new 14L New Brunswick BioFlo 300 
instrument; (3) recovering the expressed recombinant protein by centrifugation and 
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inclusion body preparation; (4) performing solubilization, reduction, and refolding in 
buffer (100 mM Tris pH 8.0, 2 mM EDTA, 0.5 M arginine hydrochloride, 0.9 mM 
oxidized glutathione, pH 10.2); (5) carrying out intermediate state preparation by 
concentration, diafiltration, and ammonium sulfate precipitation; and (6) conducting the 
purification process using metal affinity chromatography.  Purified protein will be 
characterized for identity and impurity profiles, and the toxicology lot will then be 
produced, filled, and vialed.  To remain in compliance with FDA standards for clinical-
grade products, QC measures are in place either through in-house performance of 
required assays or by contract with certified outside agencies and service providers. 
These procedures should be in accordance with recommended guidelines and are the 
basis for an IND application.  We will need to perform all efficacy, toxicity, potency, 
sterility, and stability studies described as follows.  Potency study:  cytotoxicity of 
EGFRvIII BiTE on cultured cell lines will be assayed by inhibition of protein synthesis as 
described previously.  The biological activity of EGFRvIII BiTE will be defined by the 
degree of specific lysis against EGFRvIII-expressing tumor at a set E:T ratio of 20:1 and 
BiTE concentration of 10 µg/mL.  Sterility study:  quality control will be maintained by 
performance of, or contract for, all assays for bacterial, fungal, viral, pyrogen, and DNA 
contamination.  Purified proteins are passed over an ActiCiean Etox resin (Sterogene 
Inc.) to remove any traces of endotoxins, which may be more prevalent in bacterially 
produced recombinant proteins.  Standard sterility and limulus amebocyte lysate (LAL) 
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pyrogen tests are performed in the Department of Nuclear Medicine at Duke.  These 
testing sites all meet FDA-required standards for such assays.  Stability study:  we will 
perform the following tests for the required stability verification: (1) Appearance, (2) pH, 
(3) A280, (4) SDS PAGE (Reduced and Non-reduced for both coomassie and silver 
staining), (5) SEC-HPLC (90% in the non-aggregated peak) (6) Endotoxin, (less than 5 
endotoxin units per kg) (7) IEF, (8 to 9) (8) Sterility (bacterial, fungal and viral load as 
per USP797) (9) Container Closure, (10) Osmolality, (11) Potency and stability at 37°C 
and -80°.  A Certificate of Analysis (COA) will be issued for each time point.  Statistical 
analysis:  the clinical BiTE reagent will be assessed and quality assurance will be carried 
out for biological activity as a measure of specific lysis in vitro.  Previously validated 
batches have been analyzed in triplicate and a lysis rate calculated.  Among these 
batches the mean (SD) lysis rate was 41.1% (3.6%).  Based upon methods of statistical 
process control, future batches must achieve a specific lysis of 41.1% ± 2 * 3.6% at a set 
E:T ratio of 20:1 and BiTE concentration of 10 µg/mL.   Any batch outside of these limits 
would not be acceptable.  
7.2.2 Fully Human EGFRvIII-targeted BiTEs for Antitumor Therapy 
Full murine antibodies and antibody fragments have been shown to serve as 
suitable platforms for therapy in clinical trials.  However, it is also known that innate 
properties of murine-derived antibodies can lead to the development of neutralizing 
antibody responses (i.e., human anti-murine antibody, or HAMA responses) that can 
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ultimately interfere with the ability for certain therapies to maintain efficacy over time 
(Tjandra et al., 1990).  As such, using the same methodology as described in the design 
of the murine-derived EGFRvIII BiTE, we have generated cDNA encoding a fully 
human EGFRvIII-specific BiTE, designated 139x28F11.  The antibody clones 139 (US 
2010/0111979 A1) and 28F11 are fully human antibodies with specificity for the EGFRvIII 
tumor antigen and the human CD3 complex, respectively.  28F11 has been described as 
the fully human analog for the murine OKT3 clone, and was selected in this approach 
for its ability to bind CD3 and induce T cell activation through this receptor similarly to 
OKT3.  This fully human EGFRvIII BiTE is currently in development, and will embody 
the ideal molecule for further development after it is appropriately validated.  However, 
the current murine construct could certainly be translated in human studies without this 
effort, since several murine-based scFv products are being used without significant 
adverse consequences in clinical trials.   
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Table 9:  cDNA sequence and design for a fully-human EGFRvIII-specific BiTE based 
on antibody clones 139 and 28F11. 
139 VH GAGGTGCAGGTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGG 
GGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCA 
GCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGG 
AGTGGGTCTCGGCTATTAGTGGTAGTGGTGGTAGTACAAACTACGC 
AGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAA 
GAACACACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACA 
CGGCCGTCTATTACTGTGCTGGGAGCAGTGGCTGGTCCGAGTACTG 
GGGCCAGGGAACCCTGGTCACCGTCTCCTCG 
139 VL GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAG 
GAGACAGAGTCACCATCACTTGCCGGGCTAGTCAGGGCATTAGAA 
ATAATTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGC 
GCCTGATCTATGCTGCCTCCAATTTGCAAAGTGGGGTCCCATCAAG 
GTTCACCGGCAGTGGATCTGGGACAGAATTCACTCTCATAGTCAGC 
AGCCTGCAGCCTGAAGATTTTGCGACTTATTACTGTCTACAGCATCA 
CAGTTACCCGCTCACTTCCGGCGGAGGGACCAAGGTGGAGATCAAA 
Gly4Ser GGTGGTGGCGGTTCA  
28F11 VH CAGGTGCAGCTGGTGGAGTCCGGGGGAGGCGTGGTCCAGCCTGGG 
AGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCAAGTTCAGTG 
GCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGG 
AGTGGGTGGCAGTTATATGGTATGATGGAAGTAAGAAATACTATG 
TAGACTCCGTGAAGGGCCGCTTCACCATCTCCAGAGACAATTCCA 
AGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGAC 
ACGGCTGTGTATTACTGTGCGAGACAAATGGGCTACTGGCACTTC 
GATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCA 
28F11 VL GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGG 
GGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGC 
TACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCT 
CATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCA 
GTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTA 
GAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTG 
GCCTCCGCTCACTT TCGGCGGAGGGACCAAGGTGGAGATCAAA 
The 15-mer, glycine-serine linkers typically used to bridge variable light and heavy 
domains within single-chain antibodies is omitted for simplicity. 
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7.2.3 Microdosing Objectives and Study Design 
Based on calculations from preclinical data, we would plan to administer the 
EGFRvIII BiTE to patients at a minimal therapeutic dose of 150 µg/m2, which is also the 
maximum dose allowable under regulatory restrictions for microdosing studies.  In 
collaboration with Dr. Michael Zalutsky, we have extensive experience radiolabeling 
antibody-based constructs for animal localization studies and human use (Zalutsky et 
al., 1996, Scott et al., 2007b).  We will radiolabel these constructs and inject them 
intravenously together with 111In-labeled autologous T cells as outlined in detail below.  
Subjects included in our study will be limited to patients with recurrent, biopsy-proven 
EGFRvIII expression on >10% of their cells based on IHC from biopsy or resection.  
Patient population:  Our proposed Phase 0/1 microdosing study will enroll a unique set 
of adults with recurrent supratentorial EGFRvIII+ GBM who have undergone surgical 
biopsy or excision with residual disease (>1 cm), have a Karnofsky performance status ≥ 
70, have stable or decreasing doses of steroids, have no other serious illnesses, and have 
normal OP4 and CMP.  Treatment plan:  upon enrollment, patients will be randomized 
to two groups, A or B, in a crossover, repeated measures study design.  Group A will 
receive a sequence of two treatments, first 111In-labeled T cells alone, followed by 111In-
labeled T cells with radiolabeled EGFRvIII BiTE.  Group B will receive the treatments in 
the reverse order.  Treatments will be separated by 7 days, allowing for sufficient 
clearance of the BiTE, which has a half-life of approximately 2 hours.  Following each 
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treatment, blood samples will be drawn at 1 and 6 hours, then 1, 2, and 3 days after start 
of treatment.  Daily imaging by PET and SPECT (days 1, 3, and 5) will be used to 
determine the intracerebral localization of 111In-labeled T cells and iodinated BiTE.  
Quantification of radioactivity will be assessed by previously published methods that 
calculate counts from reconstructed images based on the percentage of injected dose.  
Lymphocytes in patients’ peripheral blood will be analyzed by FACS and quantified.  
Isolated PBMC will be stained with fluorescence-labeled antibodies against cell surface 
or intracellular markers including TCR, CD3, CD4, CD8, CD56 and the activation 
marker CD69. Monitoring plan:  patients with recurrent EGFRvIII-positive GBM will be 
imaged by MRI for baseline measurements and to assess progression prior to being 
randomized to receive EGFRvIII BiTE; although the purpose of this study is not to detect 
tumor responses, any evidence of tumor response will be determined by serial measures 
of the product of the 2 largest cross-sectional diameters (Macdonald et al., 1990, Galanis 
et al., 2006).  For patients with < 0.5mm of enhancing tissue in 2 cross-sectional diameters 
in each of 2 perpendicular slices on the baseline scan, progression will be defined when 
enhancement is > 1 cm in 2 cross-sectional diameters in each of 2 perpendicular slices.  
The modified RANO criteria (Wen et al., 2010) will be used for overall assessment of 
tumor response.  Tumor progression will be documented histologically, unless there are 
clinical contraindications, to exclude inflammatory responses presenting as radiographic 
or clinical changes, which could indicate potentially toxic or therapeutic responses and 
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not tumor progression.  If tissue is obtained, it will be used to confirm tumor 
progression histologically and to assess immunologic cell infiltration and antigen escape 
using IHC.  Overall survival will be defined as time between enrollment and death, and 
will be censored at the last follow-up.  Safety monitoring:  a dose limiting toxicity (DLT) 
will be defined as any drug-related Grade IV or non-neurologic Grade III toxicity of any 
duration.  A Grade III neurologic toxicity will only be declared a DLT if not reversible 
within 4 weeks. 
7.3 Caveats for Future Clinical Trials in Brain Tumor 
Immunotherapy 
One challenge in the translation of antitumor immunotherapy has been the 
absence of a methodological framework specifically designed for early phase clinical 
studies of immune-based treatments.  Interestingly, clinical trials in immunotherapy 
have historically followed paradigms similar to those that have been established for 
chemotherapy.  This however is likely inappropriate given the vast dissimilarities 
between the two forms of treatment with regard to their respective mechanisms-of-
action and other pharmacodynamic properties.  For instance, unlike chemotherapy, 
immune-based antitumor vaccines often do not have an identifiable maximum tolerated 
dose (MTD); instead they frequently seek to identify a maximum feasible dose, based on 
the amount of “drug” that can be manufactured from limited biological material.  
Moreover, for most immunotherapies, the administered dose has not been ostensibly 
linked to endpoints including clinical efficacy or the magnitude of antitumor immune 
 159 
responses.  Lastly, again in contrast to many other types of treatment, it has been 
suggested that favorable clinical outcomes following immunologic responses are 
delayed and in some cases may occur even after radiographic evidence of tumor 
progression, drawing further attention to whether current endpoint criteria for assessing  
the impact of immune-based treatments might be adjusted to better detect significant 
responses (Wolchok et al., 2009). 
Along those lines, a notable observation in immunotherapy trials has been the 
seemingly incongruous finding in some patients of unaltered time to progression, yet 
improved overall survival.  Because this scenario is considered unusual for 
chemotherapies and other directly cytotoxic therapies, WHO or RECIST criteria 
(Eisenhauer et al., 2009) have traditionally mandated such outcomes should be labeled 
progressive disease (PD), which, due to certain conventions has become synonymous 
with drug failure.  However, in the setting of immune therapy in particular, this 
approach may be suboptimal, not only because it has the potential to dilute observed 
therapeutic effects but also to completely cease experimental therapy.  As a result, 
groups such as the Cancer Immunotherapy Consortium of the Cancer Research Institute 
have attempted to design more appropriate “immune-response criteria” to be applied 
during immunotherapy trials (Hoos et al., 2010, O'Regan et al., 2011, Wolchok et al., 
2009).  Importantly, these new criteria broaden the types of observed patterns in tumor 
growth that might qualify a response to therapy, in order to foster more accurate 
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alignment between clinical outcome (i.e., overall survival) and radiographic metrics of 
tumor progression. While not yet universally accepted, these criteria continue to expand 
in recognition and use. 
7.3.1 Considerations for Immune Monitoring 
Owing to the inherent variability associated with survival endpoints, clinical 
studies of immunotherapy for glioma have historically focused on measures of 
immunity as surrogates for objective clinical response.  Several immunological assays 
have been employed for this purpose including delayed type hypersensitivity (DTH) 
reactions, enzyme-linked immunosorbent spot (ELISpot), tetramer analysis, 
lymphoproliferative assays, intracellular cytokine staining (ICS), and an array of in vitro 
cytotoxicity assays thought to be predictive of antitumor efficacy in vivo.  While they 
have certainly provided valuable insight, none of these metrics have been universally 
validated to date, largely due to their inability to consistently correlate with clinical 
outcomes.  Numerous efforts are underway to establish alternative markers for 
antitumor immunotherapy; however, until these parameters are fully validated, care 
should be taken to avoid over-interpretation of immunologic surrogate data.   
It is reasonable to speculate that given current shortcomings, immune 
monitoring will likely transition from a predominant focus on T-cell responses to a 
broader, more global view of host immunity.  For instance, increasing attention may be 
placed on previously neglected immune cell types including monocytes, natural killer 
 161 
cells, and other effectors that may favorably contribute to antitumor immunity.  
Moreover, efforts to assess the immunological status of the brain tumor 
microenvironment—as opposed to analyses limited to cells present in peripheral 
blood—may also reveal predictive data that have been underappreciated to date.   
Importantly, it should be noted that past failures in immune monitoring may be 
as much of a result of technical limitations as they are of incomplete scientific 
understanding.  That is to say, currently available immune assays (e.g., ELISpot, ICS, 
etc.) have been shown to suffer from significant methodological inconsistencies between 
laboratories, leading to a state of generalized variability and unreliability in the 
interpretation of immune response data (Hoos et al., 2011).  To address this issue, recent 
studies have developed tools for assay harmonization that would implement 
widespread adoption of standard operating procedures; such efforts have been shown to 
significantly mitigate several of these inconsistencies (Britten et al., 2009, Hoos et al., 
2010) and should thus be strongly considered for integration into future plans for clinical 
development. 
7.4 Conclusion 
Given recent progress toward approval for other tumors, the use of 
immunotherapy to treat malignant glioma may provide a promising option for future 
study, where the need for safer, more effective treatment is great.   In order to continue 
to advance immune-based treatments, such as BiTEs, for patients with brain tumors, it 
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will be necessary to broadly address a number of limitations that pertain especially to 
the treatment of tumors in the CNS.  Among these include aspects of drug delivery, 
glioma-induced immune suppression, and methodological inconsistencies in clinical 
trial design.  Furthermore, special consideration will have to be dedicated to the use of 
vaccines and other immune-based treatment in the context of standard-of-care 
treatments including radiation and chemotherapy.  Successful treatment of these 
devastating CNS tumors will likely require a combinatorial, multi-pronged approach, 
and further studies will seek to elucidate the ways in which immune-based therapy 
might complement or even work synergistically with these existing strategies. 
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Appendix  
Permission was obtained to reproduce text and figures according to journal and 
publisher policies.  Chapter 1 contains excerpts from (Choi et al., 2009).  Chapter 2 
contains excerpts from (Choi et al., 2011).  Chapter 3 and 4 contains figures and excerpts 
from (Choi et al., 2013), for which permissions are not needed for use as part of 
dissertations according to Proceedings of the National Academy of Sciences, U.S.A. policy.   
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